<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10518077</article-id>
    <article-id pub-id-type="pmid">37610353</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btad524</article-id>
    <article-id pub-id-type="publisher-id">btad524</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Paper</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Sequence Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>MULGA, a unified multi-view graph autoencoder-based approach for identifying drug–protein interaction and drug repositioning</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Ma</surname>
          <given-names>Jiani</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="lead">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation" degree-contribution="lead">Data curation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="lead">Formal analysis</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="lead">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="lead">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software" degree-contribution="lead">Software</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="lead">Writing - original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role>
        <aff><institution>School of Information and Control Engineering, China University of Mining and Technology</institution>, Xuzhou 221116, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1847-754X</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Chen</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University</institution>, Melbourne, VIC 3800, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Yiwen</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>Climate, Air Quality Research Unit, School of Public Health and Preventive Medicine, Monash University</institution>, Melbourne, VIC 3004, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Zhikang</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University</institution>, Melbourne, VIC 3800, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Shanshan</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>Climate, Air Quality Research Unit, School of Public Health and Preventive Medicine, Monash University</institution>, Melbourne, VIC 3004, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Guo</surname>
          <given-names>Yuming</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>Climate, Air Quality Research Unit, School of Public Health and Preventive Medicine, Monash University</institution>, Melbourne, VIC 3004, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7404-5231</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Lin</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="supporting">Supervision</role>
        <aff><institution>School of Information and Control Engineering, China University of Mining and Technology</institution>, Xuzhou 221116, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Liu</surname>
          <given-names>Hui</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition" degree-contribution="lead">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="supporting">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>School of Information and Control Engineering, China University of Mining and Technology</institution>, Xuzhou 221116, <country country="CN">China</country></aff>
        <xref rid="btad524-cor1" ref-type="corresp"/>
        <!--hui.liu@cumt.edu.cn-->
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7108-3574</contrib-id>
        <name>
          <surname>Gao</surname>
          <given-names>Xin</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition" degree-contribution="supporting">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="supporting">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="supporting">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>KAUST Computational Bioscience Research Center (CBRC), King Abdullah University of Science and Technology (KAUST)</institution>, Thuwal 23955, <country country="SA">Saudi Arabia</country></aff>
        <xref rid="btad524-cor1" ref-type="corresp"/>
        <!--xin.gao@kaust.edu.sa-->
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8031-9086</contrib-id>
        <name>
          <surname>Song</surname>
          <given-names>Jiangning</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition" degree-contribution="lead">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="lead">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="lead">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="lead">Writing - review &amp; editing</role>
        <aff><institution>Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University</institution>, Melbourne, VIC 3800, <country country="AU">Australia</country></aff>
        <aff><institution>Wenzhou Medical University-Monash Biomedicine Discovery Institute (BDI) Alliance in Clinical and Experimental Biomedicine</institution>, Wenzhou 325035, <country country="CN">China</country></aff>
        <aff><institution>Monash Data Futures Institute, Monash University</institution>, Melbourne, VIC 3800, <country country="AU">Australia</country></aff>
        <xref rid="btad524-cor1" ref-type="corresp"/>
        <!--jiangning.song@monash.edu-->
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Elofsson</surname>
          <given-names>Arne</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btad524-cor1">Corresponding authors. Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia. E-mail: <email>jiangning.song@monash.edu</email> (J.S.); KAUST Computational Bioscience Research Center (CBRC), King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Saudi Arabia. E-mail: <email>xin.gao@kaust.edu.sa</email> (X.G.); School of Information and Control Engineering, China University of Mining and Technology, Xuzhou 221116, China. E-mail: <email>hui.liu@cumt.edu.cn</email> (H.L.)</corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>9</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-08-23">
      <day>23</day>
      <month>8</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>23</day>
      <month>8</month>
      <year>2023</year>
    </pub-date>
    <volume>39</volume>
    <issue>9</issue>
    <elocation-id>btad524</elocation-id>
    <history>
      <date date-type="received">
        <day>27</day>
        <month>5</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>26</day>
        <month>7</month>
        <year>2023</year>
      </date>
      <date date-type="editorial-decision">
        <day>21</day>
        <month>8</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>22</day>
        <month>8</month>
        <year>2023</year>
      </date>
      <date date-type="corrected-typeset">
        <day>22</day>
        <month>9</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btad524.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Identifying drug–protein interactions (DPIs) is a critical step in drug repositioning, which allows reuse of approved drugs that may be effective for treating a different disease and thereby alleviates the challenges of new drug development. Despite the fact that a great variety of computational approaches for DPI prediction have been proposed, key challenges, such as extendable and unbiased similarity calculation, heterogeneous information utilization, and reliable negative sample selection, remain to be addressed.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>To address these issues, we propose a novel, unified multi-view graph autoencoder framework, termed MULGA, for both DPI and drug repositioning predictions. MULGA is featured by: (i) a multi-view learning technique to effectively learn authentic drug affinity and target affinity matrices; (ii) a graph autoencoder to infer missing DPI interactions; and (iii) a new “guilty-by-association”-based negative sampling approach for selecting highly reliable non-DPIs. Benchmark experiments demonstrate that MULGA outperforms state-of-the-art methods in DPI prediction and the ablation studies verify the effectiveness of each proposed component. Importantly, we highlight the top drugs shortlisted by MULGA that target the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2), offering additional insights into and potentially useful treatment option for COVID-19. Together with the availability of datasets and source codes, we envision that MULGA can be explored as a useful tool for DPI prediction and drug repositioning.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>MULGA is publicly available for academic purposes at <ext-link xlink:href="https://github.com/jianiM/MULGA/" ext-link-type="uri">https://github.com/jianiM/MULGA/</ext-link>.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>61971422</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Drug repositioning aims to explore novel clinical applications of the approved compounds for treating different diseases and can thereby save much effort and time for new drug development (<xref rid="btad524-B25" ref-type="bibr">Pushpakom <italic toggle="yes">et al.</italic> 2019</xref>). Repositioning existing drugs necessitates accurate identification of drugs’ target proteins and drug–protein interactions (DPIs). Existing computational approaches can be broadly categorized into molecular docking-based and machine learning-based methods. Molecular docking (<xref rid="btad524-B27" ref-type="bibr">Salsbury 2010)</xref> is a traditional but important approach for predicting drug–protein binding affinities, which highly relies on the availability of 3D structures of proteins and drugs. As such, the practical application of molecular docking is limited when the 3D structures of drugs, proteins, and their physiochemical data still need to be improved. On the other hand, machine learning-based approaches construct various predictive models, such as matrix completion-based and deep learning (DL) models, using curated DPI training data. Matrix factorization and subspace learning methods have been extensively applied to DPI prediction due to their adaptability in integrating prior information. Drug similarity and protein similarity matrices are indispensable prior knowledge in the matrix completion-based DPI prediction methods, such as NRLMF (<xref rid="btad524-B21" ref-type="bibr">Liu <italic toggle="yes">et al.</italic> 2016</xref>) and SPLCMF (<xref rid="btad524-B33" ref-type="bibr">Xia <italic toggle="yes">et al.</italic> 2019</xref>), given the assumption that similar drugs tend to target similar proteins. However, obtaining an extendable and unbiased similarity matrix for proteins/drugs is challenging due to the large number of molecular and versatile physiochemical features of drugs/proteins and various similarity measures.</p>
    <p>In recent years, DL techniques have attracted considerable attention and demonstrated an emerging promise in DPI prediction due to its flexible architecture and capability of capturing useful latent features. Two primary types of DL-based approaches have been proposed for DPI prediction, including Natural Language Processing (NLP)-based DL models and Graph Neural Network (GNN)-based models. NLP-based DL models, such as DeepDTA (<xref rid="btad524-B24" ref-type="bibr">Ozturk <italic toggle="yes">et al.</italic> 2018</xref>), DeepCDA (<xref rid="btad524-B1" ref-type="bibr">Abbasi <italic toggle="yes">et al.</italic> 2020</xref>), and HyperAttentionDTI (<xref rid="btad524-B36" ref-type="bibr">Zhao <italic toggle="yes">et al.</italic> 2022</xref>), processed protein and drug SMILES (simplified molecular-input line-entry system) sequences as sentences via the NLP algorithms for extracting semantic features. However, there are two common limitations in NLP-based DL methods: (i) the syntax of the drug SMILES sequence and protein sequence is different from the natural language, which inevitably results in the omission of key characteristics during the feature learning process; and (ii) the structural and physiochemical properties of drugs and proteins are ignored by the language models. GNN-based models, such as GraphBAR (<xref rid="btad524-B28" ref-type="bibr">Son and Kim 2021</xref>), GraphDTA (<xref rid="btad524-B30" ref-type="bibr">Thin <italic toggle="yes">et al.</italic> 2021</xref>), and AttentionSiteDTI (<xref rid="btad524-B35" ref-type="bibr">Yazdani-Jahromi <italic toggle="yes">et al.</italic> 2022</xref>), were then proposed to naturally model the 3D structure of drug–target complex or drug molecules to extract the structural features of drugs and targets systematically. GraphBAR modeled the 3D structure of each drug–target binding complex as a graph, in which the nodes are the atoms of drugs and proteins within a fixed cutoff distance threshold in the binding complex. Coupled with the attention pooling mechanism, AttentionSiteDTI used the graph attention embedding networks to extract learnable feature embeddings from the graph representations of drug’s SMILES and proteins’ binding sites. However, a drug–protein binding complex often necessitates multiple large-scale, high-dimension, and sparse matrices to represent its entire structures, resulting in redundant input to the model, which will possibly lead to higher computational costs and a reduction of the model performance. To address these issues, DrugVQA (<xref rid="btad524-B37" ref-type="bibr">Zheng <italic toggle="yes">et al.</italic> 2020</xref>) used the contact map (CMAP) to present sequence-derived and structural features. However, it is essential to mention that CMAP also presents the protein structure prediction results, which may need to be sufficiently reliable for further prediction and analyses.</p>
    <p>In this study, we proposed a unified Multi-view Learning and Graph Autoencoder framework, termed MULGA, for DPI prediction and drug repositioning. By leveraging a multi-view learning module and a graph autoencoder module, MULGA provides important insights into molecular similarities in a metric-free manner and extrapolates the topological characteristics and the correlation patterns embedded in the drug–protein heterogeneous network.</p>
  </sec>
  <sec>
    <title>2 Materials and methods</title>
    <sec>
      <title>2.1 Datasets</title>
      <p>We comprehensively evaluated our method on four benchmark datasets, including one extracted from DrugBank (released on 2022.01.04; version 5.1.9) (<xref rid="btad524-B31" ref-type="bibr">Wishart <italic toggle="yes">et al.</italic> 2018</xref>), and the other three extracted from the Kinase Inhibitor Bioactivity (KIBA) dataset (<xref rid="btad524-B29" ref-type="bibr">Tang <italic toggle="yes">et al.</italic> 2014</xref>), Davis Kinase Inhibitor (Davis, version 0.3.2) dataset (<xref rid="btad524-B9" ref-type="bibr">Davis <italic toggle="yes">et al.</italic> 2011</xref>), and BindingDB dataset (<xref rid="btad524-B20" ref-type="bibr">Liu <italic toggle="yes">et al.</italic> 2007</xref>), respectively. These four benchmark datasets are introduced in detail in the following subsections.</p>
      <sec>
        <title>2.1.1 DrugBank</title>
        <p>To ensure the quality of the dataset, we manually discarded those drugs whose sequences in the Simplified Molecular-Input Line-Entry System (SMILES) format were not recognizable according to RDKit (<xref rid="btad524-B18" ref-type="bibr">Landrum 2019</xref>).To address the sparsity issue of the DPI dataset, we further retained the drugs that target at least two proteins. The sparsity was calculated as the number of unknown DPIs divided by that of all collected DPIs. The final dataset contained 6871 validated DPIs with a sparsity of 99.71%, including 1822 drugs and 1447 proteins, respectively.</p>
      </sec>
      <sec>
        <title>2.1.2 KIBA</title>
        <p>KIBA is a valuable benchmark dataset for DPI prediction. It includes comprehensive bioactivity measurements (e.g. <italic toggle="yes">K</italic>(d), <italic toggle="yes">K</italic>(i) and IC50) of 2111 kinase inhibitors against 229 kinases. Specifically, DPI pairs that have <italic toggle="yes">K</italic>(d) values &lt;30 units are considered as binding. After downloading and filtering using the Therapeutics Data Commons (TDC) tool, a drug discovery application developed by <xref rid="btad524-B15" ref-type="bibr">Huang <italic toggle="yes">et al.</italic> (2022)</xref>, we obtained 22 154 binarized DPIs involving 1720 drugs and 220 proteins.</p>
      </sec>
      <sec>
        <title>2.1.3 Davis</title>
        <p>The Davis dataset consists of wetlab-tested <italic toggle="yes">K</italic>(d) values among 72 kinase inhibitors and 442 kinases, covering more than 80% of human catalytic protein kinome. After the processing with the TDC tool, 7320 positive samples were obtained with 68 drugs and 379 proteins.</p>
      </sec>
      <sec>
        <title>2.1.4 BindingDB</title>
        <p>BindingDB serves as a public repository of experimentally measured binding affinities between small molecules (ligands) and their target biomolecules (proteins), which were collected from the literature and public datasets. It consists of <italic toggle="yes">K</italic>d values among 10 665 drugs and 1413 proteins. Furthermore, 9166 DPIs among 3400 drugs and 886 proteins were retained after being binarized and filtered with the TDC tool.</p>
        <p>As for each dataset, based on the SMILES sequences of drugs and UniProt IDs of proteins, we extracted Molecular Access System (MACCS) keys fingerprint (<xref rid="btad524-B10" ref-type="bibr">Durant <italic toggle="yes">et al.</italic> 2002</xref>), topological fingerprint (<xref rid="btad524-B5" ref-type="bibr">Carhart <italic toggle="yes">et al.</italic> 1985</xref>), and Morgan fingerprint (<xref rid="btad524-B22" ref-type="bibr">Morgan 1965</xref>) using the RDkit package. To systemically describe protein sequences and physiochemical properties, amino acid composition (AAC) (<xref rid="btad524-B22" ref-type="bibr">Morgan 1965</xref>), Moran autocorrelation (<xref rid="btad524-B12" ref-type="bibr">Feng and Zhang 2000</xref>), Composition/Transition/Distribution (CTD) (<xref rid="btad524-B4" ref-type="bibr">Cai <italic toggle="yes">et al.</italic> 2004</xref>), and pseudo-amino acid composition (PAAC) (<xref rid="btad524-B8" ref-type="bibr">Chou 2005</xref>) were calculated using the <italic toggle="yes">iLearn</italic> software package (<xref rid="btad524-B7" ref-type="bibr">Chen <italic toggle="yes">et al.</italic> 2020</xref>, <xref rid="btad524-B6" ref-type="bibr">2021</xref>). The curated DrugBank, KIBA, Davis, and BindingDB datasets and the feature extraction pipeline are accessible at <ext-link xlink:href="https://github.com/jianiM/MULGA/" ext-link-type="uri">https://github.com/jianiM/MULGA/</ext-link>.</p>
      </sec>
    </sec>
    <sec>
      <title>2.2 Overview of the MULGA framework</title>
      <p>MULGA consists of three major steps, including (i) <italic toggle="yes">feature-driven affinity matrix learning</italic>, (ii) <italic toggle="yes">DPI inference</italic>, and (iii) <italic toggle="yes">“guilty-by-association”-inspired negative sampling</italic>. Accurate and unbiased molecular affinity matrices play vital roles in DPI prediction. At the first step, MULGA leverages a multi-view technique to extract the complementary information embedded in the protein and drug features and obtain protein and drug affinity matrices in a similarity metric-free manner. A drug–protein heterogeneous network is then spontaneously constructed by incorporating known drug–protein associations and drug and protein affinity matrices. In the second step, a graph autoencoder using the GCN as the encoder is constructed to learn the low-dimensional representations of drugs and proteins to explore the topological information embedded in the heterogeneous drug–protein network. The graph autoencoder then applies a matrix tri-factorization-inspired formula as a decoder to reconstruct the DPIs. In the last step, a “<italic toggle="yes">guilty-by-association</italic>”-based negative sampling method is employed to select the reliable negative samples (i.e. non-DPIs) based on the assumption that similar drugs target similar proteins. The overall workflow of our proposed approach is illustrated in <xref rid="btad524-F1" ref-type="fig">Fig. 1</xref>.</p>
      <fig position="float" id="btad524-F1">
        <label>Figure 1.</label>
        <caption>
          <p>A schematic workflow of the MULGA methodology. The pipeline consists of two main parts: (A) affinity matrix learning and drug–protein heterogeneous matrix construction. MULGA applies the multi-view learning strategy to multiple drug fingerprints and multiple protein features to generate a drug affinity matrix and protein affinity matrix in a feature-driven way. By incorporating the affinity matrices and known DPI associations, a drug–protein heterogeneous graph is constructed. (B) DPI inference with the graph autoencoder. Taking the drug–protein heterogeneous graph as the input, MULGA uses a graph autoencoder to effectively learn the node feature embeddings and topological patterns of the input graph, and then infers the unknown DPIs using the encoder–decoder scheme.</p>
        </caption>
        <graphic xlink:href="btad524f1" position="float"/>
      </fig>
      <sec>
        <title>2.2.1 Leveraging multi-view learning to enable effective feature-driven affinity matrix learning</title>
        <p>To date, the mainstream approaches for DPI prediction are similarity-based, which deployed different metrics using various drug and protein features, such as the Jaccard similarity coefficient for binary features and the Cosine similarity coefficient for continuous features, respectively. Features extracted from different perspectives present a diverse landscape of drug and protein molecules. It is, therefore, crucial to efficiently incorporate these heterogeneous molecule features that represent different views of the molecules for inferencing DPIs. Based on the assumption that diverse drug/protein features originate from the common underlying latent drug/protein space, multi-view learning can capture consistent and complementary information by seeking a common subspace representation, that is, the drug affinity matrix and protein affinity matrix, across all views. Here, we leveraged multi-view learning techniques in our drug repositioning task. Specifically, we applied the pairwise multi-view learning approach (<xref rid="btad524-B3" ref-type="bibr">Brbic and Kopriva 2018</xref>), which builds an “agreement” matrix by using the affinity matrix of each view and balancing the trade-off between the low-rank and sparsity property constraints on the affinity matrix. The overall pipeline of the multi-view-based affinity matrix learning is illustrated in <xref rid="btad524-F1" ref-type="fig">Fig. 1A</xref>.</p>
        <p>We then elucidate the pairwise multi-view learning model used in this work. Let <inline-formula id="IE1"><mml:math id="IM1" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE2"><mml:math id="IM2" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> denote the numbers of drugs and proteins respectively. For simplicity, <inline-formula id="IE3"><mml:math id="IM3" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE4"><mml:math id="IM4" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are collectively denoted as <inline-formula id="IE5"><mml:math id="IM5" display="inline" overflow="scroll"><mml:mi>n</mml:mi></mml:math></inline-formula>, while the number of drug features and protein features are collectively denoted as <inline-formula id="IE6"><mml:math id="IM6" display="inline" overflow="scroll"><mml:mi>v</mml:mi></mml:math></inline-formula>. The pairwise multi-view learning model is shown as (1):
<disp-formula id="E1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:munder><mml:mrow><mml:mi>min</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>,</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>v</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:munder></mml:mrow><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>v</mml:mi></mml:munderover></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>β</mml:mo><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mo>*</mml:mo></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mo>β</mml:mo><mml:mo>)</mml:mo><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:munder><mml:mo>∑</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>≤</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi>i</mml:mi><mml:mo>≠</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:munder></mml:mrow><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi>F</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mi mathvariant="bold-italic">s</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="bold-italic">t</mml:mi><mml:mo>.</mml:mo><mml:mo> </mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">X</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">X</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">diag</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi mathvariant="italic">v</mml:mi><mml:mo>,</mml:mo></mml:math></disp-formula>where <inline-formula id="IE7"><mml:math id="IM7" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">X</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mo>×</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> denotes the <italic toggle="yes">i</italic>-th drug/protein feature, <inline-formula id="IE8"><mml:math id="IM8" display="inline" overflow="scroll"><mml:mi>d</mml:mi></mml:math></inline-formula> represents the dimension of the <italic toggle="yes">i</italic>-th feature, <inline-formula id="IE9"><mml:math id="IM9" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>×</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> demonstrates the drug/protein affinity matrix for view <inline-formula id="IE10"><mml:math id="IM10" display="inline" overflow="scroll"><mml:mi>i</mml:mi></mml:math></inline-formula>, while <inline-formula id="IE11"><mml:math id="IM11" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE12"><mml:math id="IM12" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are the nuclear norm and the L<sub>1</sub>-norm, respectively. <inline-formula id="IE13"><mml:math id="IM13" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is to guarantee the low-rank property of affinity matrix <inline-formula id="IE14"><mml:math id="IM14" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, while <inline-formula id="IE15"><mml:math id="IM15" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mi mathvariant="normal"> </mml:mi></mml:math></inline-formula>keeps the sparsity property of <inline-formula id="IE16"><mml:math id="IM16" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>. <italic toggle="yes">β</italic> is introduced to balance the trade-off between the low-rank property and the sparsity of every affinity matrix. Equipped with low-rank and sparse constraints, pairwise multi-view learning efficiently reduces the redundancy of the diversity of the molecular features and simultaneously extracts complementary information across various views. <inline-formula id="IE17"><mml:math id="IM17" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:munder><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mi>j</mml:mi><mml:mo>≤</mml:mo><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mi>i</mml:mi><mml:mo>≠</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:munder></mml:mrow><mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:msup></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula> is used to achieve the common consensus representation of the drug/protein affinity matrix, and <inline-formula id="IE18"><mml:math id="IM18" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">X</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">X</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> denotes that each drug can be represented as a linear combination of the other drugs from the drug space, and so as for proteins. We also used the constraint<bold><italic toggle="yes"> diag</italic></bold>(<bold><italic toggle="yes">A</italic></bold><sup>(</sup><sup><italic toggle="yes">i</italic></sup><sup>)</sup>) to avoid the trivial solution of representing a drug/protein as a linear combination of itself. Multi-view learning model described in <xref rid="E1" ref-type="disp-formula">Equation (1)</xref> conveys that without any similarity metrics, the view-specific affinity matrices <bold><italic toggle="yes">A</italic></bold><sup>(1)</sup>, <bold><italic toggle="yes">A</italic></bold><sup>(2)</sup>,…, <bold><italic toggle="yes">A</italic></bold><sup>(</sup><sup><italic toggle="yes">v</italic></sup><sup>)</sup> could be derived in an automatically feature-driven manner. The updating rule for each <inline-formula id="IE19"><mml:math id="IM19" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> (i.e. for views <bold><italic toggle="yes">A</italic></bold><sup>(1)</sup>, <bold><italic toggle="yes">A</italic></bold><sup>(2)</sup>,…, <bold><italic toggle="yes">A</italic></bold><sup>(</sup><sup><italic toggle="yes">v</italic></sup><sup>)</sup>) at the <italic toggle="yes">k</italic>-th iteration has been listed in the Supplementary File.</p>
        <p>Next, a series of affinity matrices of all views, i.e. <bold><italic toggle="yes">A</italic></bold><sup>(1)</sup>, <bold><italic toggle="yes">A</italic></bold><sup>(2)</sup>, <bold><italic toggle="yes">…</italic></bold>, <bold><italic toggle="yes">A</italic></bold><sup>(</sup><sup><italic toggle="yes">v</italic></sup><sup>)</sup>, can be obtained. Subsequently, we used three element-wise operators (e.g. max, min and average) to generate the joint affinity matrix <bold><italic toggle="yes">A</italic></bold>. By deploying pairwise multi-view learning on multiple drug and protein features, we can obtain the joint drug affinity matrix <inline-formula id="IE20"><mml:math id="IM20" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic"> </mml:mi><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">DD</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo> </mml:mo><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> and the joint protein affinity matrix <inline-formula id="IE21"><mml:math id="IM21" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">PP</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo> </mml:mo><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>. Then we applied the min-max normalization approach on <inline-formula id="IE22"><mml:math id="IM22" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">DD</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE23"><mml:math id="IM23" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">PP</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, respectively. In MULGA, the DPI matrix is denoted as a binary matrix <inline-formula id="IE24"><mml:math id="IM24" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">DP</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo> </mml:mo><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, where the validated DPIs are denoted as “1”, or “0” vice versa. Incorporating <bold><italic toggle="yes">A<sub>DP</sub></italic></bold>, <bold><italic toggle="yes">A<sub>DD</sub></italic></bold>, and <bold><italic toggle="yes">A<sub>PP</sub></italic></bold>, we built a heterogeneous drug–protein graph, where the nodes denote drugs or proteins, and the edges connecting two nodes denote the similarity between two drugs or proteins or the validated associations between them. The adjacency matrix of the heterogeneous drug–protein graph is denoted as <bold><italic toggle="yes">H</italic></bold>, where <bold><italic toggle="yes">A<sub>PD</sub></italic></bold> is the transpose of <bold><italic toggle="yes">A<sub>DP</sub></italic></bold>:
<disp-formula id="E2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>d</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>d</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow><mml:mo>.</mml:mo></mml:math></disp-formula></p>
        <p><bold><italic toggle="yes">H</italic></bold> is a symmetric matrix, which guarantees proper properties for downstream matrix calculation and can especially enhance computational efficiency. Simultaneously, it also substantially reduces the sparsity when compared to using only the association matrix <bold><italic toggle="yes">A<sub>DP</sub></italic></bold>.</p>
      </sec>
      <sec>
        <title>2.2.2 DPI inference with graph autoencoder</title>
        <p>In MUGLA, we inferred unknown DPIs using a graph autoencoder. As shown in <xref rid="btad524-F1" ref-type="fig">Fig. 1B</xref>, the encoder consists of multiple GCN layers, while the decoder is implemented by the inner-product operation. During this process, the quality of the embedding determines the quality of the reconstructed output. Therefore, if the lower dimensional embedding captures more information and learns more accurate embeddings from the input, the model performance can be significantly improved. Simultaneously, the heterogeneous drug–protein network is a graph, rather than an image or sentence, which contains the structural information the other two do not. Thereby, GCN comes naturally as an encoder to learn its embedding features. Taking the heterogeneous drug–protein graph as an input, graph autoencoder learns the compressed drug/protein embeddings in a “message-passing” way by aggregating the information from their neighbors without changing the graph structures (<xref rid="btad524-B17" ref-type="bibr">Kipf 2017</xref>). Mathematically, the layer-wise propagation rule in a graph autoencoder can be defined as (3):
<disp-formula id="E3"><label>(3)</label><mml:math id="M3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>l</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mo>σ</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mi mathvariant="bold-italic">G</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>l</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>l</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:math></disp-formula></p>
        <p>where <inline-formula id="IE25"><mml:math id="IM25" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mi mathvariant="bold-italic">G</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> denotes the normalized graph Laplacian, <bold><italic toggle="yes">G</italic></bold> is the adjacency matrix of input graph, <inline-formula id="IE26"><mml:math id="IM26" display="inline" overflow="scroll"><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="bold-italic">diag</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:munder><mml:mo>∑</mml:mo><mml:mi>j</mml:mi></mml:munder></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">G</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> represents the degree matrix, <bold><italic toggle="yes">H</italic></bold><sup>(</sup><sup><italic toggle="yes">l</italic></sup><sup>)</sup> is a feature embedding matrix, <bold><italic toggle="yes">W</italic></bold><sup>(</sup><sup><italic toggle="yes">l</italic></sup><sup>)</sup> is a learnable weight matrix, and σ denotes an activation function. Here, to efficiently filter the useful information of the heterogeneous graph, we set the affinity threshold <inline-formula id="IE27"><mml:math id="IM27" display="inline" overflow="scroll"><mml:mo>τ</mml:mo></mml:math></inline-formula> as 0.80. Based on the following:
<disp-formula id="E4"><mml:math id="M4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mtext>if</mml:mtext><mml:mo> </mml:mo><mml:mo> </mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>≥</mml:mo><mml:mo>τ</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mtext>if</mml:mtext><mml:mo> </mml:mo><mml:mo> </mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>&lt;</mml:mo><mml:mo>τ</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo> </mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mtext>if</mml:mtext><mml:mo> </mml:mo><mml:mo> </mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>≥</mml:mo><mml:mo>τ</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mtext>if</mml:mtext><mml:mo> </mml:mo><mml:mo> </mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>&lt;</mml:mo><mml:mo>τ</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:math></disp-formula>via which we obtain
<disp-formula id="E5"><label>(4)</label><mml:math id="M5" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>d</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>d</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow><mml:mo>.</mml:mo></mml:math></disp-formula></p>
        <p>The first layer receives<bold><italic toggle="yes">H</italic></bold> as input features and <inline-formula id="IE28"><mml:math id="IM28" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula> as the adjacency matrix of the input graph, respectively (i.e. <bold><italic toggle="yes">H</italic></bold><sup>(0)</sup> = <bold><italic toggle="yes">H</italic></bold> and <bold><italic toggle="yes">G</italic></bold> = <inline-formula id="IE29"><mml:math id="IM29" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula>). The multiplication of<inline-formula id="IE30"><mml:math id="IM30" display="inline" overflow="scroll"><mml:mi mathvariant="normal"> </mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mi mathvariant="bold-italic">G</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="normal">l</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, termed Laplacian smoothing, aggregates and averages the first-order neighbor information including the affinity patterns and association patterns for each node. Then the result of Laplacian smoothing is transformed by the weight matrix <bold><italic toggle="yes">W</italic></bold><sup>(</sup><sup><italic toggle="yes">l</italic></sup><sup>)</sup> and activation function σ. It is important to note that the learnable weight matrix in the first layer was set as<inline-formula id="IE31"><mml:math id="IM31" display="inline" overflow="scroll"><mml:mo> </mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>. As the result, <inline-formula id="IE32"><mml:math id="IM32" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mo>σ</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mi mathvariant="bold-italic">G</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>d</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>×</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula>. Then we set <inline-formula id="IE33"><mml:math id="IM33" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>l</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>×</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>,</mml:mo><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>L</mml:mi></mml:math></inline-formula> in the subsequent layer. The stacking of multiple graph convolutional layers increases the flow of the message. Additionally, the higher layer can capture multi-hop neighboring information. In the end, MUGLA learns the graph embedding <inline-formula id="IE34"><mml:math id="IM34" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>L</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> for drugs and proteins, where<inline-formula id="IE35"><mml:math id="IM35" display="inline" overflow="scroll"><mml:mi mathvariant="normal"> </mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>L</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, <inline-formula id="IE36"><mml:math id="IM36" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>×</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> is the drug embedding and <inline-formula id="IE37"><mml:math id="IM37" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>×</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> is the protein embedding. Additionally, the learnable weight matrix in the final layer <inline-formula id="IE38"><mml:math id="IM38" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>L</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> measures the map from drug space to the protein space. Inspired by matrix tri-factorization, MUGLA introduced an inner-product encoder to reconstruct the DPI matrix:
<disp-formula id="E6"><label>(5)</label><mml:math id="M6" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mo>*</mml:mo></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mo>σ</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mi>D</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>L</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">T</mml:mi></mml:msubsup></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:math></disp-formula>where the (<italic toggle="yes">i</italic>, <italic toggle="yes">j</italic>)-th element of <bold><italic toggle="yes">H</italic></bold>*, denoted as <italic toggle="yes">h<sub>ij</sub></italic><sup>*</sup>, is the predicted association score between the drug <italic toggle="yes">i</italic> and target <italic toggle="yes">j</italic>.</p>
      </sec>
      <sec>
        <title>2.2.3 “Guilty-by-association”-based negative sampling with the similarity information</title>
        <p>A well-designed machine-learning model highly depends on the quality of the training data, wherein the negative and positive samples are equally important. Compared to positive samples (i.e. annotated DPIs), negative samples (i.e. non-associated drug–protein pairs) are difficult to identify, posing significant challenges of testing the performance of machine learning models to predict DPIs. Most studies either directly took unlabeled DPIs as the negative samples or randomly sampled the negative DPIs from the unlabeled DPIs (<xref rid="btad524-B30" ref-type="bibr">Thin <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad524-B36" ref-type="bibr">Zhao <italic toggle="yes">et al.</italic> 2022</xref>). This will introduce data noise to distinguish the positives from negatives, thereby resulting in unsatisfactory performance of DPI prediction. To overcome this issue, we proposed a “guilty-by-association”-based negative sampling method to select reliable negative samples, and <xref rid="btad524-F2" ref-type="fig">Fig. 2</xref> illustrates its sampling process. The “guilty-by-association” paradigm indicates that if the majority of a drug’s “neighbors” (i.e. drugs with higher similarity scores) can interact with a protein, then the drug is likely to bind to that target. This notation aligns well with the observation that the drugs with similar bioactivities can bind to a shared target, even if their structures differ. Accordingly, drug’s “neighbors” that are less similar to the compared drug are less likely to bind to the common target.</p>
        <fig position="float" id="btad524-F2">
          <label>Figure 2.</label>
          <caption>
            <p>Illustration of the proposed “guilty-by-association” negative sampling scheme. Positive samples are represented by green blocks, while candidate negative samples are depicted as grey blocks. In light of the affinity scores among the selected drug and other drugs, the minimum affinity scores are circled with red, indicating the candidate drugs that are less likely to bind to the common target with the selected drugs. The sampled negative samples, obtained through the “guilty-by-association” approach, are shown as purple blocks, and the negative sampling process is protein-based, as indicated by the orange dash line, further establishing the mapping relevance of the negative samples to the existing positive samples.</p>
          </caption>
          <graphic xlink:href="btad524f2" position="float"/>
        </fig>
      </sec>
    </sec>
  </sec>
  <sec>
    <title>3 Results</title>
    <sec>
      <title>3.1 Experimental design</title>
      <p>To systematically evaluate the capability of MULGA in drug repositioning, we implemented MULGA in two experimental scenarios, including the “warm-start” and “cold-start-for-protein” scenarios on both two benchmark datasets. Particularly, in the “warm-start” scenario, we evaluated MULGA using both balanced (i.e. #positive samples:#negative samples = 1:1) and imbalanced (#positive samples:#negative samples = 1:10) datasets via stratified 10-fold cross-validation test. In each fold, the percentage of each class is identical. The performance was evaluated in terms of the area under the receiver-operating characteristic curve (AUROC) and the area under the Precision–Recall curve (AUPR) considering that AUPR is more informative than AUROC when testing on the imbalanced data (<xref rid="btad524-B11" ref-type="bibr">Fawcett, 2006</xref>, <xref rid="btad524-B26" ref-type="bibr">Saito and Rehmsmeier 2015</xref>), followed by other quantitative measurements in terms of ACC, Precision, Recall, Specificity, and F1 score. The corresponding performance results are provided in the Supplementary File.</p>
      <p>Cold start poses a challenge and obstacle in drug repositioning (<xref rid="btad524-B23" ref-type="bibr">Nguyen <italic toggle="yes">et al.</italic> 2022</xref>). Since most proteins lack the interaction knowledge with drugs, we performed the “cold-start-for-protein” experiment to reposition the existing drugs as therapeutic targets of novel proteins. Briefly, each protein can be regarded as a novel target by removing all its associated drugs. In this way, the removed proteins and their associated drugs are regarded as test samples, while the remaining DPIs are treated as training samples. Afterwards, by applying the “cold-start-for-protein” scheme to each target, we obtained 1447 AUROC values for the DrugBank dataset, 220 for KIBA, 379 for Davis, and 886 for BindingDB, respectively. Without the prior DPI association information of the novel proteins, the “cold-start-for-protein” strategy may incur catastrophic drop in the predictive performance. Nevertheless, it is more practical for the drug repositioning problem when compared with the “warm-start” scenario. The implementation details and hyperparameter tuning procedures are provided in the Supplementary File.</p>
    </sec>
    <sec>
      <title>3.2 Benchmarking MULGA with state-of-the-art methods for DPI prediction in both the “warm-start” and “cold-start-for-protein” scenarios</title>
      <p>In this section, to comprehensively evaluate the predictive performance of MULGA, we benchmarked the optimized MULGA model with six state-of-the-art methods, including DeepConv-DTI (<xref rid="btad524-B19" ref-type="bibr">Lee <italic toggle="yes">et al.</italic> 2019</xref>), LRSpNM (<xref rid="btad524-B32" ref-type="bibr">Wu <italic toggle="yes">et al.</italic> 2021</xref>), GraphDTA (<xref rid="btad524-B30" ref-type="bibr">Thin <italic toggle="yes">et al.</italic> 2021</xref>), DeepDTA (<xref rid="btad524-B24" ref-type="bibr">Ozturk <italic toggle="yes">et al.</italic> 2018</xref>), HyperAttentionDTI (<xref rid="btad524-B36" ref-type="bibr">Zhao <italic toggle="yes">et al.</italic> 2022</xref>), and MLMC (<xref rid="btad524-B34" ref-type="bibr">Yan <italic toggle="yes">et al.</italic> 2022</xref>) under both the “warm-start” and “cold-start-for-target” scenarios. The detailed hyperparameter tuning and element-wise operator determination procedures can be found in the Supplementary File. A brief introduction of those competing methods is also provided in the Supplementary File.</p>
      <p>In the “warm-start” scenario, we applied the negative sampling scheme in the training procedure for each method in order to make a fair comparison. We reported the mean value and standard variance of each method with the optimized parameter configurations on both balanced and imbalanced data settings (#postive samples:#negative samples = 1:1 for balanced data setting, and #postive samples:#negative samples = 1:10 for imbalanced data setting). The performance comparison of our method and the competing methods under both two scenarios on the DrugBank, KIBA, DAVIS, and BindingDB datasets are provided in <xref rid="btad524-F3" ref-type="fig">Fig. 3</xref> below and <xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S2–S4</xref>, respectively.</p>
      <fig position="float" id="btad524-F3">
        <label>Figure 3.</label>
        <caption>
          <p>Performance comparison of MULGA and other competing methods on DrugBank dataset. (A) The ROC and PR curves of MULGA and its competing methods on the balanced dataset. (B) The ROC and PR curves of MULGA and its competing methods on the imbalanced dataset. (C) Radar plots of MULGA and other methods on ACC, Precision, Recall, F1 score, and Specificity metrics on the balanced dataset. (D) Radar plots of MULGA and other methods on ACC, Precision, Recall, F1 score, and Specificity metrics on the imbalanced dataset. (E) Performance comparison between MULGA and its competing methods in the “cold-start-for-protein” scenario.</p>
        </caption>
        <graphic xlink:href="btad524f3" position="float"/>
      </fig>
      <p><xref rid="btad524-F3" ref-type="fig">Figure 3A and B</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S2–S4A</xref> and B illustrate the performance comparison of these seven methods in terms of the ROC and PR curves on both the balanced and imbalanced settings of DrugBank, KIBA, Davis, and BindingDB, respectively. It can be observed that MULGA showed consistent superiority with the highest AUROC scores as well as the highest AUPR scores on both balanced and imbalanced “positive:negative” ratios across the datasets. In contrast, LRSpNM, a matrix completion-based method, attained the lowest performance in all experimental settings and all datasets, presumably due to the sparseness of the DPI matrix and manually calculated (thus probably) inaccurate similarity metrics. On the DrugBank dataset, MULGA outperformed the competing methods with a relatively large margin by 4.35%–25.36% in terms of AUROC and 4.54%–30.82% in terms of AUPR on the balanced setting, and by 1.07%–21.31% in terms of AUROC and 13.98%–52.24% in terms of AUPR on the imbalanced setting, respectively. Moreover, MLMC performed a bit worse than MULGA. The excellent performance of both methods may be attributed to the incorporation of multi-faceted drug/protein features, as well as the unbiased similarity information extracted by multi-view learning methods. On the KIBA, Davis, and BindingDB datasets, MULGA also achieved a large margin of improved performance on both balanced and imbalanced datasets. The performance of these methods, in terms of ACC, Recall, Precision, F1 score, and Specificity on the balanced imbalanced datasets is shown in <xref rid="btad524-F3" ref-type="fig">Fig. 3C and D</xref> for the DrugBank dataset, and <xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S2–S4C</xref> and <xref rid="sup1" ref-type="supplementary-material">D</xref> for the KIBA, Davis, and BindingDB datasets, respectively.</p>
      <p>Based on the prior similarity information incorporated in our constructed drug–protein heterogeneous network, MULGA can further predict novel targets of candidate drugs in the “cold-start-for-protein” setting, which can be of practical importance in real-world applications. Due to its malfunction under the “cold-start-for-protein” setting, LRSpNM was excluded from the performance comparison. Taking the DrugBank dataset as an example, we obtained 1447 AUROC scores for each method by deploying the “cold-start-for-protein” scheme to each target. All the 1477 AUROC values achieved by MULGA, DeepDTA, GraphDTA, DeepConv-DTI, HyperAttentionDTI, and MLMC for the DrugBank dataset are shown in <xref rid="btad524-F3" ref-type="fig">Fig. 3E</xref>, while for the KIBA, Davis, and BindingDB datasets, AUROC distribution of six compared methods are shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S2–S4E</xref>, respectively. We can see from <xref rid="btad524-F3" ref-type="fig">Fig. 3E</xref> that the AUROC scores exhibited right-skewed distributions with values ranging from 0.8 to 1.0, and MLMC showed a slightly right-skewed distributions with the AUROC scores distributed within the interval [0.6, 0.9]. In contrast, GraphDTA, DeepConv-DTI, and HyperAttentionDTI exhibited normal distributions with the AUROC scores ranging from 0.4 to 0.8. Combined with AUROC distributions of them generated by the KIBA, Davis, and BindingDB datasets (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S2–S4E</xref>), we concluded that MULGA significantly outperformed the competing methods under the “cold-start-for protein” scenario.</p>
    </sec>
    <sec>
      <title>3.3 Importance of the multi-view strategy on the predictive performance of MULGA</title>
      <p>MULGA incorporates three types of drug features and four types of protein features for the DPI prediction in a multi-view manner. Each feature type represents a “view” that provides potentially useful information for portraying drugs or proteins. In this section, we performed a “view-ablation” experiment on the DrugBank dataset to evaluate the importance and effectiveness of each view. In brief, after removing each feature view, the MULGA were trained on the remaining features under the “warm-start” scenario. <xref rid="btad524-F4" ref-type="fig">Figure 4A</xref> shows the performance of view-ablation experiments in terms of various measures on both balanced and imbalanced datasets.</p>
      <fig position="float" id="btad524-F4">
        <label>Figure 4.</label>
        <caption>
          <p>Results of view ablation studies on DrugBank dataset. (A) Performance comparison of different view ablation studies on the balanced dataset and imbalanced dataset, respectively. The larger markers correspond to larger values for each metric. (B) Performance comparison of MULGA with our proposed “guilty-by-association” negative sampling and that with random negative sampling on the balanced dataset and imbalanced dataset, respectively. Darker blue denotes a higher score while lighter blue corresponds to a lower score. (C) TSNE visualizations of the feature space distribution of MULGA with our proposed “guilty-by-association” negative sampling and the random negative sampling.</p>
        </caption>
        <graphic xlink:href="btad524f4" position="float"/>
      </fig>
      <p>As illustrated in <xref rid="btad524-F4" ref-type="fig">Fig. 4A</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>, when compared to the MULGA model trained using all features, the performance measures all decreased to different extents upon the removal of a particular feature. This implies that each variety of features in MULGA contributes non-negligibly to DPI prediction. The results also reveal the precise similarities among drugs and proteins since they harbor rich and complementary knowledge including molecular sequence, structural and physiochemical knowledge. However, different types of features may contribute to the performance to varying degrees. After removal of the PAAC features, the performance decreased compared to all features—a decrease of 3.79% in ACC and 5.10% in AUROC in the balanced scenario, and a decrease of 5.76% in ACC and 10.18% in AUROC in the imbalanced scenario, respectively, suggesting that PAAC is the most contributing feature (i.e. “view”) to the DPI prediction in MULGA.</p>
    </sec>
    <sec>
      <title>3.4 “Guilty-by-association”-based negative sampling serves as an effective strategy for the selection of reliable negative DPIs</title>
      <p>To evaluate the effectiveness of the proposed negative sampling strategy, we compared it with the random negative sampling scheme on both balanced and imbalanced data of DrugBank dataset. The results are shown in <xref rid="btad524-F4" ref-type="fig">Fig. 4B</xref>, where dark blue cells represent higher performance and light blue cells denote lower scores. It is obvious from <xref rid="btad524-F4" ref-type="fig">Fig. 4B</xref> that the proposed negative sampling method is superior to random sampling for MULGA. To intuitively explore the rationale behind this, we utilized the t-distributed stochastic neighbor embedding (<italic toggle="yes">t</italic>-SNE) (<xref rid="btad524-B13" ref-type="bibr">Hinton 2002</xref>) to visualize the extracted feature distribution of MULGA models trained with the two negative sampling strategies under the balanced scenario in <xref rid="btad524-F4" ref-type="fig">Fig. 4C</xref>. The positive and negative DPI samples are labelled in green and red, respectively. As <xref rid="btad524-F4" ref-type="fig">Fig. 4C</xref> shows, the model trained with our “guilty-by-association” scheme generates representations with more distinguishable and clearer feature distribution. Taken together, we conclude that our proposed “guilty-by-association” negative sampling scheme is a more advanced sampling strategy under the data imbalance conditions and significant for accurate DPI prediction.</p>
    </sec>
    <sec>
      <title>3.5 “MULGA” is capable of predicting potentially effective drugs for targeting the spike glycoprotein of SARS-CoV-2</title>
      <p>In this section, we further showcase a real-world application of MULGA to repositioning potential drugs for treating COVID-19, a global health crisis that caused massive mortality of over six million people worldwide (<xref rid="btad524-B14" ref-type="bibr">Huang <italic toggle="yes">et al.</italic> 2020</xref>). COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a single-stranded RNA-enveloped virus (<xref rid="btad524-B38" ref-type="bibr">Zhu <italic toggle="yes">et al.</italic> 2020</xref>). SARS-CoV-2 encodes various proteins, including spike glycoprotein, which is localized on the cell surface and plays an important role of mediating the viral cell entry (<xref rid="btad524-B14" ref-type="bibr">Huang <italic toggle="yes">et al.</italic> 2020</xref>). We applied MULGA to predict candidate drugs that can potentially target the spike glycoprotein. Particularly, we extracted the FASTA-format spike glycoprotein sequences of SAR-CoV-2 from the UniProt database (<xref rid="btad524-B2" ref-type="bibr">Bateman <italic toggle="yes">et al.</italic> 2019</xref>), followed by the calculation of the AAC, Moran autocorrelation, CTD, and PAAC features for these sequences. The target affinity matrix was then recalculated based on the newly added sequence. Meanwhile, the blank association vector of SAR-CoV-2 and other drugs was padded into the original drug–target association matrix. Finally, MULGA was implemented on the new heterogeneous drug–target matrix equipped with the recalculated target affinity and drug–target association matrices of DrugBank dataset. The top 20 candidate drugs for the spike glycoprotein were selected based on their predicted probability. <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S5</xref> provides the ranking of those top 20 drugs, and the supporting evidence can also be found in Supplementary File. Taken together, MULGA is capable of identifying and prioritizing potentially effective drugs to target the spike glycoprotein of SARS-CoV-2 can identify potential in identifying reliable DPIs for repurposing existing drugs for treating different diseases.</p>
    </sec>
  </sec>
  <sec>
    <title>4 Discussion and conclusion</title>
    <p>An advantage of MULGA is that it can incorporate multiple heterogeneous drug features and protein features irrespective of their size and dimension. Furthermore, it can also be extended to address other association prediction tasks, e.g. drug–drug interaction prediction, peptide–protein interaction prediction and protein–protein interaction prediction. However, MULGA also has limitations: first, although MULGA could unveil the binding situation among drugs and proteins, the specific binding sites of drugs and proteins still need to be characterized. In other words, investigating the binding sites making the most significant contribution toward the DPI prediction may be more relevant for the clinical trial; second, the pairwise “multi-view” learning method used in MULGA requires the features with equal length, posing challenges of incorporating versatile drug features and protein features; third, the species-specific knowledge was not incorporated into the MULGA framework when using the DrugBank and KIBA datasets. In the future work, we plan to develop new computational frameworks to address this issue by incorporating species-specific information and examining the possibility of transferring the knowledge learned by species-specific model to other diverse organisms, and fourth, the current version of MULGA lacks desirable biological interpretability to some extent. In this regard, we plan to improve this by integrating interpretable DL and/or attention-based mechanisms in future work.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btad524_Supplementary_Data</label>
      <media xlink:href="btad524_supplementary_data.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec>
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p>None declared.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work was supported by grants from the National Science Foundation of China (61971422) and a Major Inter-Disciplinary Research Grant awarded by Monash University.</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data and code availability</title>
    <p>The DrugBank, KIBA, Davis, and BindingDB datasets and their processing pipelines are available at <ext-link xlink:href="https://github.com/jianiM/MULGA" ext-link-type="uri">https://github.com/jianiM/MULGA</ext-link>. The source code of MULGA can also be found at <ext-link xlink:href="https://github.com/jianiM/MULGA" ext-link-type="uri">https://github.com/jianiM/MULGA</ext-link>.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btad524-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abbasi</surname><given-names>K</given-names></string-name>, <string-name><surname>Razzaghi</surname><given-names>P</given-names></string-name>, <string-name><surname>Poso</surname><given-names>A</given-names></string-name></person-group><etal>et al</etal><article-title>DeepCDA: deep cross-domain compound-protein affinity prediction through LSTM and convolutional neural networks</article-title>. <source>Bioinformatics</source><year>2020</year>;<volume>36</volume>:<fpage>4633</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">32462178</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brbic</surname><given-names>M</given-names></string-name>, <string-name><surname>Kopriva</surname><given-names>I.</given-names></string-name></person-group><article-title>Multi-view low-rank sparse subspace clustering</article-title>. <source>Pattern Recognition</source><year>2018</year>;<volume>73</volume>:<fpage>247</fpage>–<lpage>58</lpage>.</mixed-citation>
    </ref>
    <ref id="btad524-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cai</surname><given-names>CZ</given-names></string-name>, <string-name><surname>Han</surname><given-names>LY</given-names></string-name>, <string-name><surname>Ji</surname><given-names>ZL</given-names></string-name></person-group><etal>et al</etal><article-title>Enzyme family classification by support vector machines</article-title>. <source>Proteins</source><year>2004</year>;<volume>55</volume>:<fpage>66</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">14997540</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carhart</surname><given-names>RE</given-names></string-name>, <string-name><surname>Smith</surname><given-names>DH</given-names></string-name>, <string-name><surname>Venkataraghavan</surname><given-names>R.</given-names></string-name></person-group><article-title>Atom pairs as molecular features in structure-activity studies: definition and applications</article-title>. <source>J Chem Inf Comput Sci</source><year>1985</year>;<volume>25</volume>:<fpage>64</fpage>–<lpage>73</lpage>.</mixed-citation>
    </ref>
    <ref id="btad524-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>P</given-names></string-name>, <string-name><surname>Li</surname><given-names>C</given-names></string-name></person-group><etal>et al</etal><article-title>iLearnPlus: a comprehensive and automated machine-learning platform for nucleic acid and protein sequence analysis, prediction and visualization</article-title>. <source>Nucleic Acids Res</source><year>2021</year>;<volume>49</volume>:<fpage>e60</fpage>.<pub-id pub-id-type="pmid">33660783</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>P</given-names></string-name>, <string-name><surname>Li</surname><given-names>F</given-names></string-name></person-group><etal>et al</etal><article-title>iLearn: an integrated platform and meta-learner for feature engineering, machine-learning analysis and modeling of DNA, RNA and protein sequence data</article-title>. <source>Brief Bioinform</source><year>2020</year>;<volume>21</volume>:<fpage>1047</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">31067315</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chou</surname><given-names>KC.</given-names></string-name></person-group><article-title>Using amphiphilic pseudo amino acid composition to predict enzyme subfamily classes</article-title>. <source>Bioinformatics</source><year>2005</year>;<volume>21</volume>:<fpage>10</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">15308540</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davis</surname><given-names>MI</given-names></string-name>, <string-name><surname>Hunt</surname><given-names>JP</given-names></string-name>, <string-name><surname>Herrgard</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>Comprehensive analysis of kinase inhibitor selectivity</article-title>. <source>Nat Biotechnol</source><year>2011</year>;<volume>29</volume>:<fpage>1046</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">22037378</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Durant</surname><given-names>JL</given-names></string-name>, <string-name><surname>Leland</surname><given-names>BA</given-names></string-name>, <string-name><surname>Henry</surname><given-names>DR</given-names></string-name></person-group><etal>et al</etal><article-title>Reoptimization of MDL keys for use in drug discovery</article-title>. <source>J Chem Inf Comput Sci</source><year>2002</year>;<volume>42</volume>:<fpage>1273</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">12444722</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fawcett</surname><given-names>T.</given-names></string-name></person-group><article-title>An introduction to ROC analysis</article-title>. <source>Pattern Recognit Lett</source><year>2006</year>;<volume>27</volume>:<fpage>861</fpage>–<lpage>74</lpage>.</mixed-citation>
    </ref>
    <ref id="btad524-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feng</surname><given-names>ZP</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>CT.</given-names></string-name></person-group><article-title>Prediction of membrane protein types based on the hydrophobic index of amino acids</article-title>. <source>J Protein Chem</source><year>2000</year>;<volume>19</volume>:<fpage>269</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">11043931</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hinton</surname><given-names>GER.</given-names></string-name></person-group><article-title>Stochastic neighbor embedding</article-title>. <source>Adv Neural Inf Process Syst</source><year>2002</year>;<volume>15</volume>:<fpage>857</fpage>–<lpage>64</lpage>.</mixed-citation>
    </ref>
    <ref id="btad524-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>C</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Li</surname><given-names>X</given-names></string-name></person-group><etal>et al</etal><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source>Lancet</source><year>2020</year>;<volume>395</volume>:<fpage>497</fpage>–<lpage>506</lpage>.<pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>K</given-names></string-name>, <string-name><surname>Fu</surname><given-names>T</given-names></string-name>, <string-name><surname>Gao</surname><given-names>W</given-names></string-name></person-group><etal>et al</etal><article-title>Artificial intelligence foundation for therapeutic science</article-title>. <source>Nat Chem Biol</source><year>2022</year>;<volume>18</volume>:<fpage>1033</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">36131149</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>C</given-names></string-name>, <string-name><surname>Xu</surname><given-names>X-F</given-names></string-name></person-group><etal>et al</etal><article-title>Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19</article-title>. <source>Acta Pharmacol Sin</source><year>2020</year>;<volume>41</volume>:<fpage>1141</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">32747721</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B17">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Kipf</surname><given-names>TN</given-names></string-name>, <string-name><surname>Welling</surname><given-names>M</given-names></string-name></person-group>. Semi-supervised classification with graph convolutional networks. <italic toggle="yes">arXiv preprint arXiv:1609.02907</italic>.</mixed-citation>
    </ref>
    <ref id="btad524-B18">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Landrum</surname><given-names>G.</given-names></string-name></person-group> RDKit: open-source cheminformatics from machine learning to chemical registration. In, <italic toggle="yes">Abstracts of Papers of the American Chemical Society</italic>. AMER CHEMICAL SOC 1155 16TH ST, NW, WASHINGTON, DC 20036 USA; 2019.</mixed-citation>
    </ref>
    <ref id="btad524-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>I</given-names></string-name>, <string-name><surname>Keum</surname><given-names>J</given-names></string-name>, <string-name><surname>Nam</surname><given-names>H.</given-names></string-name></person-group><article-title>DeepConv-DTI: prediction of drug-target interactions via deep learning with convolution on protein sequences</article-title>. <source>PLoS Comput Biol</source><year>2019</year>;<volume>15</volume>:<fpage>e1007129</fpage>.<pub-id pub-id-type="pmid">31199797</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>T</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wen</surname><given-names>X</given-names></string-name></person-group><etal>et al</etal><article-title>BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities</article-title>. <source>Nucleic Acids Res</source><year>2007</year>;<volume>35</volume>:<fpage>D198</fpage>–<lpage>201</lpage>.<pub-id pub-id-type="pmid">17145705</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wu</surname><given-names>M</given-names></string-name>, <string-name><surname>Miao</surname><given-names>C</given-names></string-name></person-group><etal>et al</etal><article-title>Neighborhood regularized logistic matrix factorization for drug-target interaction prediction</article-title>. <source>PLoS Comput Biol</source><year>2016</year>;<volume>12</volume>:<fpage>e1004760</fpage>.<pub-id pub-id-type="pmid">26872142</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morgan</surname><given-names>HL.</given-names></string-name></person-group><article-title>The generation of a unique machine description for chemical structures—a technique developed at chemical abstracts service</article-title>. <source>J Chem Doc</source><year>1965</year>;<volume>5</volume>:<fpage>107</fpage>–<lpage>13</lpage>.</mixed-citation>
    </ref>
    <ref id="btad524-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nguyen</surname><given-names>TM</given-names></string-name>, <string-name><surname>Nguyen</surname><given-names>T</given-names></string-name>, <string-name><surname>Tran</surname><given-names>T.</given-names></string-name></person-group><article-title>Mitigating cold-start problems in drug-target affinity prediction with interaction knowledge transferring</article-title>. <source>Brief Bioinform</source><year>2022</year>;<volume>23</volume>:bbac269.</mixed-citation>
    </ref>
    <ref id="btad524-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ozturk</surname><given-names>H</given-names></string-name>, <string-name><surname>Ozgur</surname><given-names>A</given-names></string-name>, <string-name><surname>Ozkirimli</surname><given-names>E.</given-names></string-name></person-group><article-title>DeepDTA: deep drug-target binding affinity prediction</article-title>. <source>Bioinformatics</source><year>2018</year>;<volume>34</volume>:<fpage>i821</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">30423097</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pushpakom</surname><given-names>S</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F</given-names></string-name>, <string-name><surname>Eyers</surname><given-names>PA</given-names></string-name></person-group><etal>et al</etal><article-title>Drug repurposing: progress, challenges and recommendations</article-title>. <source>Nat Rev Drug Discov</source><year>2019</year>;<volume>18</volume>:<fpage>41</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">30310233</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saito</surname><given-names>T</given-names></string-name>, <string-name><surname>Rehmsmeier</surname><given-names>M.</given-names></string-name></person-group><article-title>The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets</article-title>. <source>PLoS One</source><year>2015</year>;<volume>10</volume>:<fpage>e0118432</fpage>.<pub-id pub-id-type="pmid">25738806</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Salsbury</surname><given-names>FR</given-names><suffix>Jr</suffix></string-name></person-group>. <article-title>Molecular dynamics simulations of protein dynamics and their relevance to drug discovery</article-title>. <source>Curr Opin Pharmacol</source><year>2010</year>;<volume>10</volume>:<fpage>738</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">20971684</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Son</surname><given-names>J</given-names></string-name>, <string-name><surname>Kim</surname><given-names>D.</given-names></string-name></person-group><article-title>Development of a graph convolutional neural network model for efficient prediction of protein-ligand binding affinities</article-title>. <source>PLoS One</source><year>2021</year>;<volume>16</volume>:<fpage>e0249404</fpage>.<pub-id pub-id-type="pmid">33831016</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>J</given-names></string-name>, <string-name><surname>Szwajda</surname><given-names>A</given-names></string-name>, <string-name><surname>Shakyawar</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis</article-title>. <source>J Chem Inf Model</source><year>2014</year>;<volume>54</volume>:<fpage>735</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">24521231</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The UniProt Consortium.</collab></person-group><article-title>UniProt: a worldwide hub of protein knowledge</article-title>. <source>Nucleic Acids Res</source><year>2019</year>;<volume>47</volume>:<fpage>D506</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">30395287</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thin</surname><given-names>N</given-names></string-name>, <string-name><surname>Huang</surname><given-names>L</given-names></string-name>, <string-name><surname>Tomas</surname><given-names>PQ</given-names></string-name></person-group><etal>et al</etal><article-title>GraphDTA: predicting drug-target binding affinity with graph neural networks</article-title>. <source>Bioinformatics</source><year>2021</year>;<volume>37</volume>:<fpage>1140</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">33119053</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>DS</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>YD</given-names></string-name>, <string-name><surname>Guo</surname><given-names>AC</given-names></string-name></person-group><etal>et al</etal><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res</source><year>2018</year>;<volume>46</volume>:<fpage>D1074</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>G</given-names></string-name>, <string-name><surname>Yang</surname><given-names>M</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name></person-group><etal>et al</etal><article-title>De novo prediction of drug-target interactions using Laplacian regularized schatten p-Norm minimization</article-title>. <source>J Comput Biol</source><year>2021</year>;<volume>28</volume>:<fpage>660</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">33481664</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xia</surname><given-names>L-Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H</given-names></string-name></person-group><etal>et al</etal><article-title>Improved prediction of drug-target interactions using Self-Paced learning with collaborative matrix factorization</article-title>. <source>J Chem Inf Model</source><year>2019</year>;<volume>59</volume>:<fpage>3340</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">31260620</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>M</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>H</given-names></string-name></person-group><etal>et al</etal><article-title>Drug repositioning based on multi-view learning with matrix completion</article-title>. <source>Brief Bioinform</source><year>2022</year>;<volume>23</volume>.</mixed-citation>
    </ref>
    <ref id="btad524-B35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yazdani-Jahromi</surname><given-names>M</given-names></string-name>, <string-name><surname>Yousefi</surname><given-names>N</given-names></string-name>, <string-name><surname>Tayebi</surname><given-names>A</given-names></string-name></person-group><etal>et al</etal><article-title>AttentionSiteDTI: an interpretable graph-based model for drug-target interaction prediction using NLP sentence-level relation classification</article-title>. <source>Brief Bioinform</source><year>2022</year>;<volume>23</volume>:bbac272.</mixed-citation>
    </ref>
    <ref id="btad524-B36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>H</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>K</given-names></string-name></person-group><etal>et al</etal><article-title>HyperAttentionDTI: improving drug-protein interaction prediction by sequence-based deep learning with attention mechanism</article-title>. <source>Bioinformatics</source><year>2022</year>;<volume>38</volume>:<fpage>655</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">34664614</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname><given-names>S</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>Predicting drug-protein interaction using quasi-visual question answering system</article-title>. <source>Nat Mach Intell</source><year>2020</year>;<volume>2</volume>:<fpage>134</fpage>–<lpage>40</lpage>.</mixed-citation>
    </ref>
    <ref id="btad524-B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>N</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>D</given-names></string-name>, <string-name><surname>Wang</surname><given-names>W</given-names></string-name></person-group><etal>et al</etal>; <collab>China Novel Coronavirus Investigating and Research Team</collab>. <article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title>. <source>N Engl J Med</source><year>2020</year>;<volume>382</volume>:<fpage>727</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10518077</article-id>
    <article-id pub-id-type="pmid">37610353</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btad524</article-id>
    <article-id pub-id-type="publisher-id">btad524</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Paper</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Sequence Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>MULGA, a unified multi-view graph autoencoder-based approach for identifying drug–protein interaction and drug repositioning</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Ma</surname>
          <given-names>Jiani</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="lead">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation" degree-contribution="lead">Data curation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="lead">Formal analysis</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="lead">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="lead">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software" degree-contribution="lead">Software</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="lead">Writing - original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="equal">Writing - review &amp; editing</role>
        <aff><institution>School of Information and Control Engineering, China University of Mining and Technology</institution>, Xuzhou 221116, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1847-754X</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Chen</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University</institution>, Melbourne, VIC 3800, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Yiwen</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>Climate, Air Quality Research Unit, School of Public Health and Preventive Medicine, Monash University</institution>, Melbourne, VIC 3004, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Zhikang</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University</institution>, Melbourne, VIC 3800, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Shanshan</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>Climate, Air Quality Research Unit, School of Public Health and Preventive Medicine, Monash University</institution>, Melbourne, VIC 3004, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Guo</surname>
          <given-names>Yuming</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>Climate, Air Quality Research Unit, School of Public Health and Preventive Medicine, Monash University</institution>, Melbourne, VIC 3004, <country country="AU">Australia</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7404-5231</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Lin</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="supporting">Supervision</role>
        <aff><institution>School of Information and Control Engineering, China University of Mining and Technology</institution>, Xuzhou 221116, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Liu</surname>
          <given-names>Hui</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition" degree-contribution="lead">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="supporting">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>School of Information and Control Engineering, China University of Mining and Technology</institution>, Xuzhou 221116, <country country="CN">China</country></aff>
        <xref rid="btad524-cor1" ref-type="corresp"/>
        <!--hui.liu@cumt.edu.cn-->
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7108-3574</contrib-id>
        <name>
          <surname>Gao</surname>
          <given-names>Xin</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition" degree-contribution="supporting">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="supporting">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="supporting">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role>
        <aff><institution>KAUST Computational Bioscience Research Center (CBRC), King Abdullah University of Science and Technology (KAUST)</institution>, Thuwal 23955, <country country="SA">Saudi Arabia</country></aff>
        <xref rid="btad524-cor1" ref-type="corresp"/>
        <!--xin.gao@kaust.edu.sa-->
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8031-9086</contrib-id>
        <name>
          <surname>Song</surname>
          <given-names>Jiangning</given-names>
        </name>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition" degree-contribution="lead">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="supporting">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="lead">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="lead">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="lead">Writing - review &amp; editing</role>
        <aff><institution>Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University</institution>, Melbourne, VIC 3800, <country country="AU">Australia</country></aff>
        <aff><institution>Wenzhou Medical University-Monash Biomedicine Discovery Institute (BDI) Alliance in Clinical and Experimental Biomedicine</institution>, Wenzhou 325035, <country country="CN">China</country></aff>
        <aff><institution>Monash Data Futures Institute, Monash University</institution>, Melbourne, VIC 3800, <country country="AU">Australia</country></aff>
        <xref rid="btad524-cor1" ref-type="corresp"/>
        <!--jiangning.song@monash.edu-->
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Elofsson</surname>
          <given-names>Arne</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btad524-cor1">Corresponding authors. Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia. E-mail: <email>jiangning.song@monash.edu</email> (J.S.); KAUST Computational Bioscience Research Center (CBRC), King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Saudi Arabia. E-mail: <email>xin.gao@kaust.edu.sa</email> (X.G.); School of Information and Control Engineering, China University of Mining and Technology, Xuzhou 221116, China. E-mail: <email>hui.liu@cumt.edu.cn</email> (H.L.)</corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>9</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-08-23">
      <day>23</day>
      <month>8</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>23</day>
      <month>8</month>
      <year>2023</year>
    </pub-date>
    <volume>39</volume>
    <issue>9</issue>
    <elocation-id>btad524</elocation-id>
    <history>
      <date date-type="received">
        <day>27</day>
        <month>5</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>26</day>
        <month>7</month>
        <year>2023</year>
      </date>
      <date date-type="editorial-decision">
        <day>21</day>
        <month>8</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>22</day>
        <month>8</month>
        <year>2023</year>
      </date>
      <date date-type="corrected-typeset">
        <day>22</day>
        <month>9</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btad524.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Identifying drug–protein interactions (DPIs) is a critical step in drug repositioning, which allows reuse of approved drugs that may be effective for treating a different disease and thereby alleviates the challenges of new drug development. Despite the fact that a great variety of computational approaches for DPI prediction have been proposed, key challenges, such as extendable and unbiased similarity calculation, heterogeneous information utilization, and reliable negative sample selection, remain to be addressed.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>To address these issues, we propose a novel, unified multi-view graph autoencoder framework, termed MULGA, for both DPI and drug repositioning predictions. MULGA is featured by: (i) a multi-view learning technique to effectively learn authentic drug affinity and target affinity matrices; (ii) a graph autoencoder to infer missing DPI interactions; and (iii) a new “guilty-by-association”-based negative sampling approach for selecting highly reliable non-DPIs. Benchmark experiments demonstrate that MULGA outperforms state-of-the-art methods in DPI prediction and the ablation studies verify the effectiveness of each proposed component. Importantly, we highlight the top drugs shortlisted by MULGA that target the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2), offering additional insights into and potentially useful treatment option for COVID-19. Together with the availability of datasets and source codes, we envision that MULGA can be explored as a useful tool for DPI prediction and drug repositioning.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>MULGA is publicly available for academic purposes at <ext-link xlink:href="https://github.com/jianiM/MULGA/" ext-link-type="uri">https://github.com/jianiM/MULGA/</ext-link>.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>61971422</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Drug repositioning aims to explore novel clinical applications of the approved compounds for treating different diseases and can thereby save much effort and time for new drug development (<xref rid="btad524-B25" ref-type="bibr">Pushpakom <italic toggle="yes">et al.</italic> 2019</xref>). Repositioning existing drugs necessitates accurate identification of drugs’ target proteins and drug–protein interactions (DPIs). Existing computational approaches can be broadly categorized into molecular docking-based and machine learning-based methods. Molecular docking (<xref rid="btad524-B27" ref-type="bibr">Salsbury 2010)</xref> is a traditional but important approach for predicting drug–protein binding affinities, which highly relies on the availability of 3D structures of proteins and drugs. As such, the practical application of molecular docking is limited when the 3D structures of drugs, proteins, and their physiochemical data still need to be improved. On the other hand, machine learning-based approaches construct various predictive models, such as matrix completion-based and deep learning (DL) models, using curated DPI training data. Matrix factorization and subspace learning methods have been extensively applied to DPI prediction due to their adaptability in integrating prior information. Drug similarity and protein similarity matrices are indispensable prior knowledge in the matrix completion-based DPI prediction methods, such as NRLMF (<xref rid="btad524-B21" ref-type="bibr">Liu <italic toggle="yes">et al.</italic> 2016</xref>) and SPLCMF (<xref rid="btad524-B33" ref-type="bibr">Xia <italic toggle="yes">et al.</italic> 2019</xref>), given the assumption that similar drugs tend to target similar proteins. However, obtaining an extendable and unbiased similarity matrix for proteins/drugs is challenging due to the large number of molecular and versatile physiochemical features of drugs/proteins and various similarity measures.</p>
    <p>In recent years, DL techniques have attracted considerable attention and demonstrated an emerging promise in DPI prediction due to its flexible architecture and capability of capturing useful latent features. Two primary types of DL-based approaches have been proposed for DPI prediction, including Natural Language Processing (NLP)-based DL models and Graph Neural Network (GNN)-based models. NLP-based DL models, such as DeepDTA (<xref rid="btad524-B24" ref-type="bibr">Ozturk <italic toggle="yes">et al.</italic> 2018</xref>), DeepCDA (<xref rid="btad524-B1" ref-type="bibr">Abbasi <italic toggle="yes">et al.</italic> 2020</xref>), and HyperAttentionDTI (<xref rid="btad524-B36" ref-type="bibr">Zhao <italic toggle="yes">et al.</italic> 2022</xref>), processed protein and drug SMILES (simplified molecular-input line-entry system) sequences as sentences via the NLP algorithms for extracting semantic features. However, there are two common limitations in NLP-based DL methods: (i) the syntax of the drug SMILES sequence and protein sequence is different from the natural language, which inevitably results in the omission of key characteristics during the feature learning process; and (ii) the structural and physiochemical properties of drugs and proteins are ignored by the language models. GNN-based models, such as GraphBAR (<xref rid="btad524-B28" ref-type="bibr">Son and Kim 2021</xref>), GraphDTA (<xref rid="btad524-B30" ref-type="bibr">Thin <italic toggle="yes">et al.</italic> 2021</xref>), and AttentionSiteDTI (<xref rid="btad524-B35" ref-type="bibr">Yazdani-Jahromi <italic toggle="yes">et al.</italic> 2022</xref>), were then proposed to naturally model the 3D structure of drug–target complex or drug molecules to extract the structural features of drugs and targets systematically. GraphBAR modeled the 3D structure of each drug–target binding complex as a graph, in which the nodes are the atoms of drugs and proteins within a fixed cutoff distance threshold in the binding complex. Coupled with the attention pooling mechanism, AttentionSiteDTI used the graph attention embedding networks to extract learnable feature embeddings from the graph representations of drug’s SMILES and proteins’ binding sites. However, a drug–protein binding complex often necessitates multiple large-scale, high-dimension, and sparse matrices to represent its entire structures, resulting in redundant input to the model, which will possibly lead to higher computational costs and a reduction of the model performance. To address these issues, DrugVQA (<xref rid="btad524-B37" ref-type="bibr">Zheng <italic toggle="yes">et al.</italic> 2020</xref>) used the contact map (CMAP) to present sequence-derived and structural features. However, it is essential to mention that CMAP also presents the protein structure prediction results, which may need to be sufficiently reliable for further prediction and analyses.</p>
    <p>In this study, we proposed a unified Multi-view Learning and Graph Autoencoder framework, termed MULGA, for DPI prediction and drug repositioning. By leveraging a multi-view learning module and a graph autoencoder module, MULGA provides important insights into molecular similarities in a metric-free manner and extrapolates the topological characteristics and the correlation patterns embedded in the drug–protein heterogeneous network.</p>
  </sec>
  <sec>
    <title>2 Materials and methods</title>
    <sec>
      <title>2.1 Datasets</title>
      <p>We comprehensively evaluated our method on four benchmark datasets, including one extracted from DrugBank (released on 2022.01.04; version 5.1.9) (<xref rid="btad524-B31" ref-type="bibr">Wishart <italic toggle="yes">et al.</italic> 2018</xref>), and the other three extracted from the Kinase Inhibitor Bioactivity (KIBA) dataset (<xref rid="btad524-B29" ref-type="bibr">Tang <italic toggle="yes">et al.</italic> 2014</xref>), Davis Kinase Inhibitor (Davis, version 0.3.2) dataset (<xref rid="btad524-B9" ref-type="bibr">Davis <italic toggle="yes">et al.</italic> 2011</xref>), and BindingDB dataset (<xref rid="btad524-B20" ref-type="bibr">Liu <italic toggle="yes">et al.</italic> 2007</xref>), respectively. These four benchmark datasets are introduced in detail in the following subsections.</p>
      <sec>
        <title>2.1.1 DrugBank</title>
        <p>To ensure the quality of the dataset, we manually discarded those drugs whose sequences in the Simplified Molecular-Input Line-Entry System (SMILES) format were not recognizable according to RDKit (<xref rid="btad524-B18" ref-type="bibr">Landrum 2019</xref>).To address the sparsity issue of the DPI dataset, we further retained the drugs that target at least two proteins. The sparsity was calculated as the number of unknown DPIs divided by that of all collected DPIs. The final dataset contained 6871 validated DPIs with a sparsity of 99.71%, including 1822 drugs and 1447 proteins, respectively.</p>
      </sec>
      <sec>
        <title>2.1.2 KIBA</title>
        <p>KIBA is a valuable benchmark dataset for DPI prediction. It includes comprehensive bioactivity measurements (e.g. <italic toggle="yes">K</italic>(d), <italic toggle="yes">K</italic>(i) and IC50) of 2111 kinase inhibitors against 229 kinases. Specifically, DPI pairs that have <italic toggle="yes">K</italic>(d) values &lt;30 units are considered as binding. After downloading and filtering using the Therapeutics Data Commons (TDC) tool, a drug discovery application developed by <xref rid="btad524-B15" ref-type="bibr">Huang <italic toggle="yes">et al.</italic> (2022)</xref>, we obtained 22 154 binarized DPIs involving 1720 drugs and 220 proteins.</p>
      </sec>
      <sec>
        <title>2.1.3 Davis</title>
        <p>The Davis dataset consists of wetlab-tested <italic toggle="yes">K</italic>(d) values among 72 kinase inhibitors and 442 kinases, covering more than 80% of human catalytic protein kinome. After the processing with the TDC tool, 7320 positive samples were obtained with 68 drugs and 379 proteins.</p>
      </sec>
      <sec>
        <title>2.1.4 BindingDB</title>
        <p>BindingDB serves as a public repository of experimentally measured binding affinities between small molecules (ligands) and their target biomolecules (proteins), which were collected from the literature and public datasets. It consists of <italic toggle="yes">K</italic>d values among 10 665 drugs and 1413 proteins. Furthermore, 9166 DPIs among 3400 drugs and 886 proteins were retained after being binarized and filtered with the TDC tool.</p>
        <p>As for each dataset, based on the SMILES sequences of drugs and UniProt IDs of proteins, we extracted Molecular Access System (MACCS) keys fingerprint (<xref rid="btad524-B10" ref-type="bibr">Durant <italic toggle="yes">et al.</italic> 2002</xref>), topological fingerprint (<xref rid="btad524-B5" ref-type="bibr">Carhart <italic toggle="yes">et al.</italic> 1985</xref>), and Morgan fingerprint (<xref rid="btad524-B22" ref-type="bibr">Morgan 1965</xref>) using the RDkit package. To systemically describe protein sequences and physiochemical properties, amino acid composition (AAC) (<xref rid="btad524-B22" ref-type="bibr">Morgan 1965</xref>), Moran autocorrelation (<xref rid="btad524-B12" ref-type="bibr">Feng and Zhang 2000</xref>), Composition/Transition/Distribution (CTD) (<xref rid="btad524-B4" ref-type="bibr">Cai <italic toggle="yes">et al.</italic> 2004</xref>), and pseudo-amino acid composition (PAAC) (<xref rid="btad524-B8" ref-type="bibr">Chou 2005</xref>) were calculated using the <italic toggle="yes">iLearn</italic> software package (<xref rid="btad524-B7" ref-type="bibr">Chen <italic toggle="yes">et al.</italic> 2020</xref>, <xref rid="btad524-B6" ref-type="bibr">2021</xref>). The curated DrugBank, KIBA, Davis, and BindingDB datasets and the feature extraction pipeline are accessible at <ext-link xlink:href="https://github.com/jianiM/MULGA/" ext-link-type="uri">https://github.com/jianiM/MULGA/</ext-link>.</p>
      </sec>
    </sec>
    <sec>
      <title>2.2 Overview of the MULGA framework</title>
      <p>MULGA consists of three major steps, including (i) <italic toggle="yes">feature-driven affinity matrix learning</italic>, (ii) <italic toggle="yes">DPI inference</italic>, and (iii) <italic toggle="yes">“guilty-by-association”-inspired negative sampling</italic>. Accurate and unbiased molecular affinity matrices play vital roles in DPI prediction. At the first step, MULGA leverages a multi-view technique to extract the complementary information embedded in the protein and drug features and obtain protein and drug affinity matrices in a similarity metric-free manner. A drug–protein heterogeneous network is then spontaneously constructed by incorporating known drug–protein associations and drug and protein affinity matrices. In the second step, a graph autoencoder using the GCN as the encoder is constructed to learn the low-dimensional representations of drugs and proteins to explore the topological information embedded in the heterogeneous drug–protein network. The graph autoencoder then applies a matrix tri-factorization-inspired formula as a decoder to reconstruct the DPIs. In the last step, a “<italic toggle="yes">guilty-by-association</italic>”-based negative sampling method is employed to select the reliable negative samples (i.e. non-DPIs) based on the assumption that similar drugs target similar proteins. The overall workflow of our proposed approach is illustrated in <xref rid="btad524-F1" ref-type="fig">Fig. 1</xref>.</p>
      <fig position="float" id="btad524-F1">
        <label>Figure 1.</label>
        <caption>
          <p>A schematic workflow of the MULGA methodology. The pipeline consists of two main parts: (A) affinity matrix learning and drug–protein heterogeneous matrix construction. MULGA applies the multi-view learning strategy to multiple drug fingerprints and multiple protein features to generate a drug affinity matrix and protein affinity matrix in a feature-driven way. By incorporating the affinity matrices and known DPI associations, a drug–protein heterogeneous graph is constructed. (B) DPI inference with the graph autoencoder. Taking the drug–protein heterogeneous graph as the input, MULGA uses a graph autoencoder to effectively learn the node feature embeddings and topological patterns of the input graph, and then infers the unknown DPIs using the encoder–decoder scheme.</p>
        </caption>
        <graphic xlink:href="btad524f1" position="float"/>
      </fig>
      <sec>
        <title>2.2.1 Leveraging multi-view learning to enable effective feature-driven affinity matrix learning</title>
        <p>To date, the mainstream approaches for DPI prediction are similarity-based, which deployed different metrics using various drug and protein features, such as the Jaccard similarity coefficient for binary features and the Cosine similarity coefficient for continuous features, respectively. Features extracted from different perspectives present a diverse landscape of drug and protein molecules. It is, therefore, crucial to efficiently incorporate these heterogeneous molecule features that represent different views of the molecules for inferencing DPIs. Based on the assumption that diverse drug/protein features originate from the common underlying latent drug/protein space, multi-view learning can capture consistent and complementary information by seeking a common subspace representation, that is, the drug affinity matrix and protein affinity matrix, across all views. Here, we leveraged multi-view learning techniques in our drug repositioning task. Specifically, we applied the pairwise multi-view learning approach (<xref rid="btad524-B3" ref-type="bibr">Brbic and Kopriva 2018</xref>), which builds an “agreement” matrix by using the affinity matrix of each view and balancing the trade-off between the low-rank and sparsity property constraints on the affinity matrix. The overall pipeline of the multi-view-based affinity matrix learning is illustrated in <xref rid="btad524-F1" ref-type="fig">Fig. 1A</xref>.</p>
        <p>We then elucidate the pairwise multi-view learning model used in this work. Let <inline-formula id="IE1"><mml:math id="IM1" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE2"><mml:math id="IM2" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> denote the numbers of drugs and proteins respectively. For simplicity, <inline-formula id="IE3"><mml:math id="IM3" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE4"><mml:math id="IM4" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are collectively denoted as <inline-formula id="IE5"><mml:math id="IM5" display="inline" overflow="scroll"><mml:mi>n</mml:mi></mml:math></inline-formula>, while the number of drug features and protein features are collectively denoted as <inline-formula id="IE6"><mml:math id="IM6" display="inline" overflow="scroll"><mml:mi>v</mml:mi></mml:math></inline-formula>. The pairwise multi-view learning model is shown as (1):
<disp-formula id="E1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:munder><mml:mrow><mml:mi>min</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>,</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>v</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:munder></mml:mrow><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>v</mml:mi></mml:munderover></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>β</mml:mo><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mo>*</mml:mo></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mo>β</mml:mo><mml:mo>)</mml:mo><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:munder><mml:mo>∑</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>≤</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi>i</mml:mi><mml:mo>≠</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:munder></mml:mrow><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi>F</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mi mathvariant="bold-italic">s</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="bold-italic">t</mml:mi><mml:mo>.</mml:mo><mml:mo> </mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">X</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">X</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">diag</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi mathvariant="italic">v</mml:mi><mml:mo>,</mml:mo></mml:math></disp-formula>where <inline-formula id="IE7"><mml:math id="IM7" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">X</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mo>×</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> denotes the <italic toggle="yes">i</italic>-th drug/protein feature, <inline-formula id="IE8"><mml:math id="IM8" display="inline" overflow="scroll"><mml:mi>d</mml:mi></mml:math></inline-formula> represents the dimension of the <italic toggle="yes">i</italic>-th feature, <inline-formula id="IE9"><mml:math id="IM9" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>×</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> demonstrates the drug/protein affinity matrix for view <inline-formula id="IE10"><mml:math id="IM10" display="inline" overflow="scroll"><mml:mi>i</mml:mi></mml:math></inline-formula>, while <inline-formula id="IE11"><mml:math id="IM11" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE12"><mml:math id="IM12" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are the nuclear norm and the L<sub>1</sub>-norm, respectively. <inline-formula id="IE13"><mml:math id="IM13" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is to guarantee the low-rank property of affinity matrix <inline-formula id="IE14"><mml:math id="IM14" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, while <inline-formula id="IE15"><mml:math id="IM15" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mi mathvariant="normal"> </mml:mi></mml:math></inline-formula>keeps the sparsity property of <inline-formula id="IE16"><mml:math id="IM16" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>. <italic toggle="yes">β</italic> is introduced to balance the trade-off between the low-rank property and the sparsity of every affinity matrix. Equipped with low-rank and sparse constraints, pairwise multi-view learning efficiently reduces the redundancy of the diversity of the molecular features and simultaneously extracts complementary information across various views. <inline-formula id="IE17"><mml:math id="IM17" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:munder><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mi>j</mml:mi><mml:mo>≤</mml:mo><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mi>i</mml:mi><mml:mo>≠</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:munder></mml:mrow><mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:msup></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula> is used to achieve the common consensus representation of the drug/protein affinity matrix, and <inline-formula id="IE18"><mml:math id="IM18" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">X</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">X</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> denotes that each drug can be represented as a linear combination of the other drugs from the drug space, and so as for proteins. We also used the constraint<bold><italic toggle="yes"> diag</italic></bold>(<bold><italic toggle="yes">A</italic></bold><sup>(</sup><sup><italic toggle="yes">i</italic></sup><sup>)</sup>) to avoid the trivial solution of representing a drug/protein as a linear combination of itself. Multi-view learning model described in <xref rid="E1" ref-type="disp-formula">Equation (1)</xref> conveys that without any similarity metrics, the view-specific affinity matrices <bold><italic toggle="yes">A</italic></bold><sup>(1)</sup>, <bold><italic toggle="yes">A</italic></bold><sup>(2)</sup>,…, <bold><italic toggle="yes">A</italic></bold><sup>(</sup><sup><italic toggle="yes">v</italic></sup><sup>)</sup> could be derived in an automatically feature-driven manner. The updating rule for each <inline-formula id="IE19"><mml:math id="IM19" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> (i.e. for views <bold><italic toggle="yes">A</italic></bold><sup>(1)</sup>, <bold><italic toggle="yes">A</italic></bold><sup>(2)</sup>,…, <bold><italic toggle="yes">A</italic></bold><sup>(</sup><sup><italic toggle="yes">v</italic></sup><sup>)</sup>) at the <italic toggle="yes">k</italic>-th iteration has been listed in the Supplementary File.</p>
        <p>Next, a series of affinity matrices of all views, i.e. <bold><italic toggle="yes">A</italic></bold><sup>(1)</sup>, <bold><italic toggle="yes">A</italic></bold><sup>(2)</sup>, <bold><italic toggle="yes">…</italic></bold>, <bold><italic toggle="yes">A</italic></bold><sup>(</sup><sup><italic toggle="yes">v</italic></sup><sup>)</sup>, can be obtained. Subsequently, we used three element-wise operators (e.g. max, min and average) to generate the joint affinity matrix <bold><italic toggle="yes">A</italic></bold>. By deploying pairwise multi-view learning on multiple drug and protein features, we can obtain the joint drug affinity matrix <inline-formula id="IE20"><mml:math id="IM20" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic"> </mml:mi><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">DD</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo> </mml:mo><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> and the joint protein affinity matrix <inline-formula id="IE21"><mml:math id="IM21" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">PP</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo> </mml:mo><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>. Then we applied the min-max normalization approach on <inline-formula id="IE22"><mml:math id="IM22" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">DD</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE23"><mml:math id="IM23" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">PP</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, respectively. In MULGA, the DPI matrix is denoted as a binary matrix <inline-formula id="IE24"><mml:math id="IM24" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">DP</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo> </mml:mo><mml:mo>∈</mml:mo><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, where the validated DPIs are denoted as “1”, or “0” vice versa. Incorporating <bold><italic toggle="yes">A<sub>DP</sub></italic></bold>, <bold><italic toggle="yes">A<sub>DD</sub></italic></bold>, and <bold><italic toggle="yes">A<sub>PP</sub></italic></bold>, we built a heterogeneous drug–protein graph, where the nodes denote drugs or proteins, and the edges connecting two nodes denote the similarity between two drugs or proteins or the validated associations between them. The adjacency matrix of the heterogeneous drug–protein graph is denoted as <bold><italic toggle="yes">H</italic></bold>, where <bold><italic toggle="yes">A<sub>PD</sub></italic></bold> is the transpose of <bold><italic toggle="yes">A<sub>DP</sub></italic></bold>:
<disp-formula id="E2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>d</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>d</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow><mml:mo>.</mml:mo></mml:math></disp-formula></p>
        <p><bold><italic toggle="yes">H</italic></bold> is a symmetric matrix, which guarantees proper properties for downstream matrix calculation and can especially enhance computational efficiency. Simultaneously, it also substantially reduces the sparsity when compared to using only the association matrix <bold><italic toggle="yes">A<sub>DP</sub></italic></bold>.</p>
      </sec>
      <sec>
        <title>2.2.2 DPI inference with graph autoencoder</title>
        <p>In MUGLA, we inferred unknown DPIs using a graph autoencoder. As shown in <xref rid="btad524-F1" ref-type="fig">Fig. 1B</xref>, the encoder consists of multiple GCN layers, while the decoder is implemented by the inner-product operation. During this process, the quality of the embedding determines the quality of the reconstructed output. Therefore, if the lower dimensional embedding captures more information and learns more accurate embeddings from the input, the model performance can be significantly improved. Simultaneously, the heterogeneous drug–protein network is a graph, rather than an image or sentence, which contains the structural information the other two do not. Thereby, GCN comes naturally as an encoder to learn its embedding features. Taking the heterogeneous drug–protein graph as an input, graph autoencoder learns the compressed drug/protein embeddings in a “message-passing” way by aggregating the information from their neighbors without changing the graph structures (<xref rid="btad524-B17" ref-type="bibr">Kipf 2017</xref>). Mathematically, the layer-wise propagation rule in a graph autoencoder can be defined as (3):
<disp-formula id="E3"><label>(3)</label><mml:math id="M3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>l</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mo>σ</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mi mathvariant="bold-italic">G</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>l</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>l</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:math></disp-formula></p>
        <p>where <inline-formula id="IE25"><mml:math id="IM25" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mi mathvariant="bold-italic">G</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> denotes the normalized graph Laplacian, <bold><italic toggle="yes">G</italic></bold> is the adjacency matrix of input graph, <inline-formula id="IE26"><mml:math id="IM26" display="inline" overflow="scroll"><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="bold-italic">diag</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:munder><mml:mo>∑</mml:mo><mml:mi>j</mml:mi></mml:munder></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">G</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> represents the degree matrix, <bold><italic toggle="yes">H</italic></bold><sup>(</sup><sup><italic toggle="yes">l</italic></sup><sup>)</sup> is a feature embedding matrix, <bold><italic toggle="yes">W</italic></bold><sup>(</sup><sup><italic toggle="yes">l</italic></sup><sup>)</sup> is a learnable weight matrix, and σ denotes an activation function. Here, to efficiently filter the useful information of the heterogeneous graph, we set the affinity threshold <inline-formula id="IE27"><mml:math id="IM27" display="inline" overflow="scroll"><mml:mo>τ</mml:mo></mml:math></inline-formula> as 0.80. Based on the following:
<disp-formula id="E4"><mml:math id="M4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mtext>if</mml:mtext><mml:mo> </mml:mo><mml:mo> </mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>≥</mml:mo><mml:mo>τ</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mtext>if</mml:mtext><mml:mo> </mml:mo><mml:mo> </mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>&lt;</mml:mo><mml:mo>τ</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo> </mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mtext>if</mml:mtext><mml:mo> </mml:mo><mml:mo> </mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>≥</mml:mo><mml:mo>τ</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mtext>if</mml:mtext><mml:mo> </mml:mo><mml:mo> </mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>&lt;</mml:mo><mml:mo>τ</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:math></disp-formula>via which we obtain
<disp-formula id="E5"><label>(4)</label><mml:math id="M5" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>d</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>d</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow><mml:mo>.</mml:mo></mml:math></disp-formula></p>
        <p>The first layer receives<bold><italic toggle="yes">H</italic></bold> as input features and <inline-formula id="IE28"><mml:math id="IM28" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula> as the adjacency matrix of the input graph, respectively (i.e. <bold><italic toggle="yes">H</italic></bold><sup>(0)</sup> = <bold><italic toggle="yes">H</italic></bold> and <bold><italic toggle="yes">G</italic></bold> = <inline-formula id="IE29"><mml:math id="IM29" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula>). The multiplication of<inline-formula id="IE30"><mml:math id="IM30" display="inline" overflow="scroll"><mml:mi mathvariant="normal"> </mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mi mathvariant="bold-italic">G</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="normal">l</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, termed Laplacian smoothing, aggregates and averages the first-order neighbor information including the affinity patterns and association patterns for each node. Then the result of Laplacian smoothing is transformed by the weight matrix <bold><italic toggle="yes">W</italic></bold><sup>(</sup><sup><italic toggle="yes">l</italic></sup><sup>)</sup> and activation function σ. It is important to note that the learnable weight matrix in the first layer was set as<inline-formula id="IE31"><mml:math id="IM31" display="inline" overflow="scroll"><mml:mo> </mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>. As the result, <inline-formula id="IE32"><mml:math id="IM32" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mo>σ</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mi mathvariant="bold-italic">G</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>d</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>×</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula>. Then we set <inline-formula id="IE33"><mml:math id="IM33" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>l</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>×</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>,</mml:mo><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>L</mml:mi></mml:math></inline-formula> in the subsequent layer. The stacking of multiple graph convolutional layers increases the flow of the message. Additionally, the higher layer can capture multi-hop neighboring information. In the end, MUGLA learns the graph embedding <inline-formula id="IE34"><mml:math id="IM34" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>L</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> for drugs and proteins, where<inline-formula id="IE35"><mml:math id="IM35" display="inline" overflow="scroll"><mml:mi mathvariant="normal"> </mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>L</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo><mml:mo>×</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, <inline-formula id="IE36"><mml:math id="IM36" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>×</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> is the drug embedding and <inline-formula id="IE37"><mml:math id="IM37" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>∈</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>×</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> is the protein embedding. Additionally, the learnable weight matrix in the final layer <inline-formula id="IE38"><mml:math id="IM38" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>L</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> measures the map from drug space to the protein space. Inspired by matrix tri-factorization, MUGLA introduced an inner-product encoder to reconstruct the DPI matrix:
<disp-formula id="E6"><label>(5)</label><mml:math id="M6" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mo>*</mml:mo></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mo>σ</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mi>D</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>L</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi></mml:mrow><mml:mi mathvariant="bold-italic">P</mml:mi><mml:mi mathvariant="bold-italic">T</mml:mi></mml:msubsup></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:math></disp-formula>where the (<italic toggle="yes">i</italic>, <italic toggle="yes">j</italic>)-th element of <bold><italic toggle="yes">H</italic></bold>*, denoted as <italic toggle="yes">h<sub>ij</sub></italic><sup>*</sup>, is the predicted association score between the drug <italic toggle="yes">i</italic> and target <italic toggle="yes">j</italic>.</p>
      </sec>
      <sec>
        <title>2.2.3 “Guilty-by-association”-based negative sampling with the similarity information</title>
        <p>A well-designed machine-learning model highly depends on the quality of the training data, wherein the negative and positive samples are equally important. Compared to positive samples (i.e. annotated DPIs), negative samples (i.e. non-associated drug–protein pairs) are difficult to identify, posing significant challenges of testing the performance of machine learning models to predict DPIs. Most studies either directly took unlabeled DPIs as the negative samples or randomly sampled the negative DPIs from the unlabeled DPIs (<xref rid="btad524-B30" ref-type="bibr">Thin <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad524-B36" ref-type="bibr">Zhao <italic toggle="yes">et al.</italic> 2022</xref>). This will introduce data noise to distinguish the positives from negatives, thereby resulting in unsatisfactory performance of DPI prediction. To overcome this issue, we proposed a “guilty-by-association”-based negative sampling method to select reliable negative samples, and <xref rid="btad524-F2" ref-type="fig">Fig. 2</xref> illustrates its sampling process. The “guilty-by-association” paradigm indicates that if the majority of a drug’s “neighbors” (i.e. drugs with higher similarity scores) can interact with a protein, then the drug is likely to bind to that target. This notation aligns well with the observation that the drugs with similar bioactivities can bind to a shared target, even if their structures differ. Accordingly, drug’s “neighbors” that are less similar to the compared drug are less likely to bind to the common target.</p>
        <fig position="float" id="btad524-F2">
          <label>Figure 2.</label>
          <caption>
            <p>Illustration of the proposed “guilty-by-association” negative sampling scheme. Positive samples are represented by green blocks, while candidate negative samples are depicted as grey blocks. In light of the affinity scores among the selected drug and other drugs, the minimum affinity scores are circled with red, indicating the candidate drugs that are less likely to bind to the common target with the selected drugs. The sampled negative samples, obtained through the “guilty-by-association” approach, are shown as purple blocks, and the negative sampling process is protein-based, as indicated by the orange dash line, further establishing the mapping relevance of the negative samples to the existing positive samples.</p>
          </caption>
          <graphic xlink:href="btad524f2" position="float"/>
        </fig>
      </sec>
    </sec>
  </sec>
  <sec>
    <title>3 Results</title>
    <sec>
      <title>3.1 Experimental design</title>
      <p>To systematically evaluate the capability of MULGA in drug repositioning, we implemented MULGA in two experimental scenarios, including the “warm-start” and “cold-start-for-protein” scenarios on both two benchmark datasets. Particularly, in the “warm-start” scenario, we evaluated MULGA using both balanced (i.e. #positive samples:#negative samples = 1:1) and imbalanced (#positive samples:#negative samples = 1:10) datasets via stratified 10-fold cross-validation test. In each fold, the percentage of each class is identical. The performance was evaluated in terms of the area under the receiver-operating characteristic curve (AUROC) and the area under the Precision–Recall curve (AUPR) considering that AUPR is more informative than AUROC when testing on the imbalanced data (<xref rid="btad524-B11" ref-type="bibr">Fawcett, 2006</xref>, <xref rid="btad524-B26" ref-type="bibr">Saito and Rehmsmeier 2015</xref>), followed by other quantitative measurements in terms of ACC, Precision, Recall, Specificity, and F1 score. The corresponding performance results are provided in the Supplementary File.</p>
      <p>Cold start poses a challenge and obstacle in drug repositioning (<xref rid="btad524-B23" ref-type="bibr">Nguyen <italic toggle="yes">et al.</italic> 2022</xref>). Since most proteins lack the interaction knowledge with drugs, we performed the “cold-start-for-protein” experiment to reposition the existing drugs as therapeutic targets of novel proteins. Briefly, each protein can be regarded as a novel target by removing all its associated drugs. In this way, the removed proteins and their associated drugs are regarded as test samples, while the remaining DPIs are treated as training samples. Afterwards, by applying the “cold-start-for-protein” scheme to each target, we obtained 1447 AUROC values for the DrugBank dataset, 220 for KIBA, 379 for Davis, and 886 for BindingDB, respectively. Without the prior DPI association information of the novel proteins, the “cold-start-for-protein” strategy may incur catastrophic drop in the predictive performance. Nevertheless, it is more practical for the drug repositioning problem when compared with the “warm-start” scenario. The implementation details and hyperparameter tuning procedures are provided in the Supplementary File.</p>
    </sec>
    <sec>
      <title>3.2 Benchmarking MULGA with state-of-the-art methods for DPI prediction in both the “warm-start” and “cold-start-for-protein” scenarios</title>
      <p>In this section, to comprehensively evaluate the predictive performance of MULGA, we benchmarked the optimized MULGA model with six state-of-the-art methods, including DeepConv-DTI (<xref rid="btad524-B19" ref-type="bibr">Lee <italic toggle="yes">et al.</italic> 2019</xref>), LRSpNM (<xref rid="btad524-B32" ref-type="bibr">Wu <italic toggle="yes">et al.</italic> 2021</xref>), GraphDTA (<xref rid="btad524-B30" ref-type="bibr">Thin <italic toggle="yes">et al.</italic> 2021</xref>), DeepDTA (<xref rid="btad524-B24" ref-type="bibr">Ozturk <italic toggle="yes">et al.</italic> 2018</xref>), HyperAttentionDTI (<xref rid="btad524-B36" ref-type="bibr">Zhao <italic toggle="yes">et al.</italic> 2022</xref>), and MLMC (<xref rid="btad524-B34" ref-type="bibr">Yan <italic toggle="yes">et al.</italic> 2022</xref>) under both the “warm-start” and “cold-start-for-target” scenarios. The detailed hyperparameter tuning and element-wise operator determination procedures can be found in the Supplementary File. A brief introduction of those competing methods is also provided in the Supplementary File.</p>
      <p>In the “warm-start” scenario, we applied the negative sampling scheme in the training procedure for each method in order to make a fair comparison. We reported the mean value and standard variance of each method with the optimized parameter configurations on both balanced and imbalanced data settings (#postive samples:#negative samples = 1:1 for balanced data setting, and #postive samples:#negative samples = 1:10 for imbalanced data setting). The performance comparison of our method and the competing methods under both two scenarios on the DrugBank, KIBA, DAVIS, and BindingDB datasets are provided in <xref rid="btad524-F3" ref-type="fig">Fig. 3</xref> below and <xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S2–S4</xref>, respectively.</p>
      <fig position="float" id="btad524-F3">
        <label>Figure 3.</label>
        <caption>
          <p>Performance comparison of MULGA and other competing methods on DrugBank dataset. (A) The ROC and PR curves of MULGA and its competing methods on the balanced dataset. (B) The ROC and PR curves of MULGA and its competing methods on the imbalanced dataset. (C) Radar plots of MULGA and other methods on ACC, Precision, Recall, F1 score, and Specificity metrics on the balanced dataset. (D) Radar plots of MULGA and other methods on ACC, Precision, Recall, F1 score, and Specificity metrics on the imbalanced dataset. (E) Performance comparison between MULGA and its competing methods in the “cold-start-for-protein” scenario.</p>
        </caption>
        <graphic xlink:href="btad524f3" position="float"/>
      </fig>
      <p><xref rid="btad524-F3" ref-type="fig">Figure 3A and B</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S2–S4A</xref> and B illustrate the performance comparison of these seven methods in terms of the ROC and PR curves on both the balanced and imbalanced settings of DrugBank, KIBA, Davis, and BindingDB, respectively. It can be observed that MULGA showed consistent superiority with the highest AUROC scores as well as the highest AUPR scores on both balanced and imbalanced “positive:negative” ratios across the datasets. In contrast, LRSpNM, a matrix completion-based method, attained the lowest performance in all experimental settings and all datasets, presumably due to the sparseness of the DPI matrix and manually calculated (thus probably) inaccurate similarity metrics. On the DrugBank dataset, MULGA outperformed the competing methods with a relatively large margin by 4.35%–25.36% in terms of AUROC and 4.54%–30.82% in terms of AUPR on the balanced setting, and by 1.07%–21.31% in terms of AUROC and 13.98%–52.24% in terms of AUPR on the imbalanced setting, respectively. Moreover, MLMC performed a bit worse than MULGA. The excellent performance of both methods may be attributed to the incorporation of multi-faceted drug/protein features, as well as the unbiased similarity information extracted by multi-view learning methods. On the KIBA, Davis, and BindingDB datasets, MULGA also achieved a large margin of improved performance on both balanced and imbalanced datasets. The performance of these methods, in terms of ACC, Recall, Precision, F1 score, and Specificity on the balanced imbalanced datasets is shown in <xref rid="btad524-F3" ref-type="fig">Fig. 3C and D</xref> for the DrugBank dataset, and <xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S2–S4C</xref> and <xref rid="sup1" ref-type="supplementary-material">D</xref> for the KIBA, Davis, and BindingDB datasets, respectively.</p>
      <p>Based on the prior similarity information incorporated in our constructed drug–protein heterogeneous network, MULGA can further predict novel targets of candidate drugs in the “cold-start-for-protein” setting, which can be of practical importance in real-world applications. Due to its malfunction under the “cold-start-for-protein” setting, LRSpNM was excluded from the performance comparison. Taking the DrugBank dataset as an example, we obtained 1447 AUROC scores for each method by deploying the “cold-start-for-protein” scheme to each target. All the 1477 AUROC values achieved by MULGA, DeepDTA, GraphDTA, DeepConv-DTI, HyperAttentionDTI, and MLMC for the DrugBank dataset are shown in <xref rid="btad524-F3" ref-type="fig">Fig. 3E</xref>, while for the KIBA, Davis, and BindingDB datasets, AUROC distribution of six compared methods are shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S2–S4E</xref>, respectively. We can see from <xref rid="btad524-F3" ref-type="fig">Fig. 3E</xref> that the AUROC scores exhibited right-skewed distributions with values ranging from 0.8 to 1.0, and MLMC showed a slightly right-skewed distributions with the AUROC scores distributed within the interval [0.6, 0.9]. In contrast, GraphDTA, DeepConv-DTI, and HyperAttentionDTI exhibited normal distributions with the AUROC scores ranging from 0.4 to 0.8. Combined with AUROC distributions of them generated by the KIBA, Davis, and BindingDB datasets (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S2–S4E</xref>), we concluded that MULGA significantly outperformed the competing methods under the “cold-start-for protein” scenario.</p>
    </sec>
    <sec>
      <title>3.3 Importance of the multi-view strategy on the predictive performance of MULGA</title>
      <p>MULGA incorporates three types of drug features and four types of protein features for the DPI prediction in a multi-view manner. Each feature type represents a “view” that provides potentially useful information for portraying drugs or proteins. In this section, we performed a “view-ablation” experiment on the DrugBank dataset to evaluate the importance and effectiveness of each view. In brief, after removing each feature view, the MULGA were trained on the remaining features under the “warm-start” scenario. <xref rid="btad524-F4" ref-type="fig">Figure 4A</xref> shows the performance of view-ablation experiments in terms of various measures on both balanced and imbalanced datasets.</p>
      <fig position="float" id="btad524-F4">
        <label>Figure 4.</label>
        <caption>
          <p>Results of view ablation studies on DrugBank dataset. (A) Performance comparison of different view ablation studies on the balanced dataset and imbalanced dataset, respectively. The larger markers correspond to larger values for each metric. (B) Performance comparison of MULGA with our proposed “guilty-by-association” negative sampling and that with random negative sampling on the balanced dataset and imbalanced dataset, respectively. Darker blue denotes a higher score while lighter blue corresponds to a lower score. (C) TSNE visualizations of the feature space distribution of MULGA with our proposed “guilty-by-association” negative sampling and the random negative sampling.</p>
        </caption>
        <graphic xlink:href="btad524f4" position="float"/>
      </fig>
      <p>As illustrated in <xref rid="btad524-F4" ref-type="fig">Fig. 4A</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>, when compared to the MULGA model trained using all features, the performance measures all decreased to different extents upon the removal of a particular feature. This implies that each variety of features in MULGA contributes non-negligibly to DPI prediction. The results also reveal the precise similarities among drugs and proteins since they harbor rich and complementary knowledge including molecular sequence, structural and physiochemical knowledge. However, different types of features may contribute to the performance to varying degrees. After removal of the PAAC features, the performance decreased compared to all features—a decrease of 3.79% in ACC and 5.10% in AUROC in the balanced scenario, and a decrease of 5.76% in ACC and 10.18% in AUROC in the imbalanced scenario, respectively, suggesting that PAAC is the most contributing feature (i.e. “view”) to the DPI prediction in MULGA.</p>
    </sec>
    <sec>
      <title>3.4 “Guilty-by-association”-based negative sampling serves as an effective strategy for the selection of reliable negative DPIs</title>
      <p>To evaluate the effectiveness of the proposed negative sampling strategy, we compared it with the random negative sampling scheme on both balanced and imbalanced data of DrugBank dataset. The results are shown in <xref rid="btad524-F4" ref-type="fig">Fig. 4B</xref>, where dark blue cells represent higher performance and light blue cells denote lower scores. It is obvious from <xref rid="btad524-F4" ref-type="fig">Fig. 4B</xref> that the proposed negative sampling method is superior to random sampling for MULGA. To intuitively explore the rationale behind this, we utilized the t-distributed stochastic neighbor embedding (<italic toggle="yes">t</italic>-SNE) (<xref rid="btad524-B13" ref-type="bibr">Hinton 2002</xref>) to visualize the extracted feature distribution of MULGA models trained with the two negative sampling strategies under the balanced scenario in <xref rid="btad524-F4" ref-type="fig">Fig. 4C</xref>. The positive and negative DPI samples are labelled in green and red, respectively. As <xref rid="btad524-F4" ref-type="fig">Fig. 4C</xref> shows, the model trained with our “guilty-by-association” scheme generates representations with more distinguishable and clearer feature distribution. Taken together, we conclude that our proposed “guilty-by-association” negative sampling scheme is a more advanced sampling strategy under the data imbalance conditions and significant for accurate DPI prediction.</p>
    </sec>
    <sec>
      <title>3.5 “MULGA” is capable of predicting potentially effective drugs for targeting the spike glycoprotein of SARS-CoV-2</title>
      <p>In this section, we further showcase a real-world application of MULGA to repositioning potential drugs for treating COVID-19, a global health crisis that caused massive mortality of over six million people worldwide (<xref rid="btad524-B14" ref-type="bibr">Huang <italic toggle="yes">et al.</italic> 2020</xref>). COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a single-stranded RNA-enveloped virus (<xref rid="btad524-B38" ref-type="bibr">Zhu <italic toggle="yes">et al.</italic> 2020</xref>). SARS-CoV-2 encodes various proteins, including spike glycoprotein, which is localized on the cell surface and plays an important role of mediating the viral cell entry (<xref rid="btad524-B14" ref-type="bibr">Huang <italic toggle="yes">et al.</italic> 2020</xref>). We applied MULGA to predict candidate drugs that can potentially target the spike glycoprotein. Particularly, we extracted the FASTA-format spike glycoprotein sequences of SAR-CoV-2 from the UniProt database (<xref rid="btad524-B2" ref-type="bibr">Bateman <italic toggle="yes">et al.</italic> 2019</xref>), followed by the calculation of the AAC, Moran autocorrelation, CTD, and PAAC features for these sequences. The target affinity matrix was then recalculated based on the newly added sequence. Meanwhile, the blank association vector of SAR-CoV-2 and other drugs was padded into the original drug–target association matrix. Finally, MULGA was implemented on the new heterogeneous drug–target matrix equipped with the recalculated target affinity and drug–target association matrices of DrugBank dataset. The top 20 candidate drugs for the spike glycoprotein were selected based on their predicted probability. <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S5</xref> provides the ranking of those top 20 drugs, and the supporting evidence can also be found in Supplementary File. Taken together, MULGA is capable of identifying and prioritizing potentially effective drugs to target the spike glycoprotein of SARS-CoV-2 can identify potential in identifying reliable DPIs for repurposing existing drugs for treating different diseases.</p>
    </sec>
  </sec>
  <sec>
    <title>4 Discussion and conclusion</title>
    <p>An advantage of MULGA is that it can incorporate multiple heterogeneous drug features and protein features irrespective of their size and dimension. Furthermore, it can also be extended to address other association prediction tasks, e.g. drug–drug interaction prediction, peptide–protein interaction prediction and protein–protein interaction prediction. However, MULGA also has limitations: first, although MULGA could unveil the binding situation among drugs and proteins, the specific binding sites of drugs and proteins still need to be characterized. In other words, investigating the binding sites making the most significant contribution toward the DPI prediction may be more relevant for the clinical trial; second, the pairwise “multi-view” learning method used in MULGA requires the features with equal length, posing challenges of incorporating versatile drug features and protein features; third, the species-specific knowledge was not incorporated into the MULGA framework when using the DrugBank and KIBA datasets. In the future work, we plan to develop new computational frameworks to address this issue by incorporating species-specific information and examining the possibility of transferring the knowledge learned by species-specific model to other diverse organisms, and fourth, the current version of MULGA lacks desirable biological interpretability to some extent. In this regard, we plan to improve this by integrating interpretable DL and/or attention-based mechanisms in future work.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btad524_Supplementary_Data</label>
      <media xlink:href="btad524_supplementary_data.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec>
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p>None declared.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work was supported by grants from the National Science Foundation of China (61971422) and a Major Inter-Disciplinary Research Grant awarded by Monash University.</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data and code availability</title>
    <p>The DrugBank, KIBA, Davis, and BindingDB datasets and their processing pipelines are available at <ext-link xlink:href="https://github.com/jianiM/MULGA" ext-link-type="uri">https://github.com/jianiM/MULGA</ext-link>. The source code of MULGA can also be found at <ext-link xlink:href="https://github.com/jianiM/MULGA" ext-link-type="uri">https://github.com/jianiM/MULGA</ext-link>.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btad524-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abbasi</surname><given-names>K</given-names></string-name>, <string-name><surname>Razzaghi</surname><given-names>P</given-names></string-name>, <string-name><surname>Poso</surname><given-names>A</given-names></string-name></person-group><etal>et al</etal><article-title>DeepCDA: deep cross-domain compound-protein affinity prediction through LSTM and convolutional neural networks</article-title>. <source>Bioinformatics</source><year>2020</year>;<volume>36</volume>:<fpage>4633</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">32462178</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brbic</surname><given-names>M</given-names></string-name>, <string-name><surname>Kopriva</surname><given-names>I.</given-names></string-name></person-group><article-title>Multi-view low-rank sparse subspace clustering</article-title>. <source>Pattern Recognition</source><year>2018</year>;<volume>73</volume>:<fpage>247</fpage>–<lpage>58</lpage>.</mixed-citation>
    </ref>
    <ref id="btad524-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cai</surname><given-names>CZ</given-names></string-name>, <string-name><surname>Han</surname><given-names>LY</given-names></string-name>, <string-name><surname>Ji</surname><given-names>ZL</given-names></string-name></person-group><etal>et al</etal><article-title>Enzyme family classification by support vector machines</article-title>. <source>Proteins</source><year>2004</year>;<volume>55</volume>:<fpage>66</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">14997540</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carhart</surname><given-names>RE</given-names></string-name>, <string-name><surname>Smith</surname><given-names>DH</given-names></string-name>, <string-name><surname>Venkataraghavan</surname><given-names>R.</given-names></string-name></person-group><article-title>Atom pairs as molecular features in structure-activity studies: definition and applications</article-title>. <source>J Chem Inf Comput Sci</source><year>1985</year>;<volume>25</volume>:<fpage>64</fpage>–<lpage>73</lpage>.</mixed-citation>
    </ref>
    <ref id="btad524-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>P</given-names></string-name>, <string-name><surname>Li</surname><given-names>C</given-names></string-name></person-group><etal>et al</etal><article-title>iLearnPlus: a comprehensive and automated machine-learning platform for nucleic acid and protein sequence analysis, prediction and visualization</article-title>. <source>Nucleic Acids Res</source><year>2021</year>;<volume>49</volume>:<fpage>e60</fpage>.<pub-id pub-id-type="pmid">33660783</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>P</given-names></string-name>, <string-name><surname>Li</surname><given-names>F</given-names></string-name></person-group><etal>et al</etal><article-title>iLearn: an integrated platform and meta-learner for feature engineering, machine-learning analysis and modeling of DNA, RNA and protein sequence data</article-title>. <source>Brief Bioinform</source><year>2020</year>;<volume>21</volume>:<fpage>1047</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">31067315</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chou</surname><given-names>KC.</given-names></string-name></person-group><article-title>Using amphiphilic pseudo amino acid composition to predict enzyme subfamily classes</article-title>. <source>Bioinformatics</source><year>2005</year>;<volume>21</volume>:<fpage>10</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">15308540</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davis</surname><given-names>MI</given-names></string-name>, <string-name><surname>Hunt</surname><given-names>JP</given-names></string-name>, <string-name><surname>Herrgard</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>Comprehensive analysis of kinase inhibitor selectivity</article-title>. <source>Nat Biotechnol</source><year>2011</year>;<volume>29</volume>:<fpage>1046</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">22037378</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Durant</surname><given-names>JL</given-names></string-name>, <string-name><surname>Leland</surname><given-names>BA</given-names></string-name>, <string-name><surname>Henry</surname><given-names>DR</given-names></string-name></person-group><etal>et al</etal><article-title>Reoptimization of MDL keys for use in drug discovery</article-title>. <source>J Chem Inf Comput Sci</source><year>2002</year>;<volume>42</volume>:<fpage>1273</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">12444722</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fawcett</surname><given-names>T.</given-names></string-name></person-group><article-title>An introduction to ROC analysis</article-title>. <source>Pattern Recognit Lett</source><year>2006</year>;<volume>27</volume>:<fpage>861</fpage>–<lpage>74</lpage>.</mixed-citation>
    </ref>
    <ref id="btad524-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feng</surname><given-names>ZP</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>CT.</given-names></string-name></person-group><article-title>Prediction of membrane protein types based on the hydrophobic index of amino acids</article-title>. <source>J Protein Chem</source><year>2000</year>;<volume>19</volume>:<fpage>269</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">11043931</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hinton</surname><given-names>GER.</given-names></string-name></person-group><article-title>Stochastic neighbor embedding</article-title>. <source>Adv Neural Inf Process Syst</source><year>2002</year>;<volume>15</volume>:<fpage>857</fpage>–<lpage>64</lpage>.</mixed-citation>
    </ref>
    <ref id="btad524-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>C</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Li</surname><given-names>X</given-names></string-name></person-group><etal>et al</etal><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source>Lancet</source><year>2020</year>;<volume>395</volume>:<fpage>497</fpage>–<lpage>506</lpage>.<pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>K</given-names></string-name>, <string-name><surname>Fu</surname><given-names>T</given-names></string-name>, <string-name><surname>Gao</surname><given-names>W</given-names></string-name></person-group><etal>et al</etal><article-title>Artificial intelligence foundation for therapeutic science</article-title>. <source>Nat Chem Biol</source><year>2022</year>;<volume>18</volume>:<fpage>1033</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">36131149</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>C</given-names></string-name>, <string-name><surname>Xu</surname><given-names>X-F</given-names></string-name></person-group><etal>et al</etal><article-title>Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19</article-title>. <source>Acta Pharmacol Sin</source><year>2020</year>;<volume>41</volume>:<fpage>1141</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">32747721</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B17">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Kipf</surname><given-names>TN</given-names></string-name>, <string-name><surname>Welling</surname><given-names>M</given-names></string-name></person-group>. Semi-supervised classification with graph convolutional networks. <italic toggle="yes">arXiv preprint arXiv:1609.02907</italic>.</mixed-citation>
    </ref>
    <ref id="btad524-B18">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Landrum</surname><given-names>G.</given-names></string-name></person-group> RDKit: open-source cheminformatics from machine learning to chemical registration. In, <italic toggle="yes">Abstracts of Papers of the American Chemical Society</italic>. AMER CHEMICAL SOC 1155 16TH ST, NW, WASHINGTON, DC 20036 USA; 2019.</mixed-citation>
    </ref>
    <ref id="btad524-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>I</given-names></string-name>, <string-name><surname>Keum</surname><given-names>J</given-names></string-name>, <string-name><surname>Nam</surname><given-names>H.</given-names></string-name></person-group><article-title>DeepConv-DTI: prediction of drug-target interactions via deep learning with convolution on protein sequences</article-title>. <source>PLoS Comput Biol</source><year>2019</year>;<volume>15</volume>:<fpage>e1007129</fpage>.<pub-id pub-id-type="pmid">31199797</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>T</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wen</surname><given-names>X</given-names></string-name></person-group><etal>et al</etal><article-title>BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities</article-title>. <source>Nucleic Acids Res</source><year>2007</year>;<volume>35</volume>:<fpage>D198</fpage>–<lpage>201</lpage>.<pub-id pub-id-type="pmid">17145705</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wu</surname><given-names>M</given-names></string-name>, <string-name><surname>Miao</surname><given-names>C</given-names></string-name></person-group><etal>et al</etal><article-title>Neighborhood regularized logistic matrix factorization for drug-target interaction prediction</article-title>. <source>PLoS Comput Biol</source><year>2016</year>;<volume>12</volume>:<fpage>e1004760</fpage>.<pub-id pub-id-type="pmid">26872142</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morgan</surname><given-names>HL.</given-names></string-name></person-group><article-title>The generation of a unique machine description for chemical structures—a technique developed at chemical abstracts service</article-title>. <source>J Chem Doc</source><year>1965</year>;<volume>5</volume>:<fpage>107</fpage>–<lpage>13</lpage>.</mixed-citation>
    </ref>
    <ref id="btad524-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nguyen</surname><given-names>TM</given-names></string-name>, <string-name><surname>Nguyen</surname><given-names>T</given-names></string-name>, <string-name><surname>Tran</surname><given-names>T.</given-names></string-name></person-group><article-title>Mitigating cold-start problems in drug-target affinity prediction with interaction knowledge transferring</article-title>. <source>Brief Bioinform</source><year>2022</year>;<volume>23</volume>:bbac269.</mixed-citation>
    </ref>
    <ref id="btad524-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ozturk</surname><given-names>H</given-names></string-name>, <string-name><surname>Ozgur</surname><given-names>A</given-names></string-name>, <string-name><surname>Ozkirimli</surname><given-names>E.</given-names></string-name></person-group><article-title>DeepDTA: deep drug-target binding affinity prediction</article-title>. <source>Bioinformatics</source><year>2018</year>;<volume>34</volume>:<fpage>i821</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">30423097</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pushpakom</surname><given-names>S</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F</given-names></string-name>, <string-name><surname>Eyers</surname><given-names>PA</given-names></string-name></person-group><etal>et al</etal><article-title>Drug repurposing: progress, challenges and recommendations</article-title>. <source>Nat Rev Drug Discov</source><year>2019</year>;<volume>18</volume>:<fpage>41</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">30310233</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saito</surname><given-names>T</given-names></string-name>, <string-name><surname>Rehmsmeier</surname><given-names>M.</given-names></string-name></person-group><article-title>The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets</article-title>. <source>PLoS One</source><year>2015</year>;<volume>10</volume>:<fpage>e0118432</fpage>.<pub-id pub-id-type="pmid">25738806</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Salsbury</surname><given-names>FR</given-names><suffix>Jr</suffix></string-name></person-group>. <article-title>Molecular dynamics simulations of protein dynamics and their relevance to drug discovery</article-title>. <source>Curr Opin Pharmacol</source><year>2010</year>;<volume>10</volume>:<fpage>738</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">20971684</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Son</surname><given-names>J</given-names></string-name>, <string-name><surname>Kim</surname><given-names>D.</given-names></string-name></person-group><article-title>Development of a graph convolutional neural network model for efficient prediction of protein-ligand binding affinities</article-title>. <source>PLoS One</source><year>2021</year>;<volume>16</volume>:<fpage>e0249404</fpage>.<pub-id pub-id-type="pmid">33831016</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>J</given-names></string-name>, <string-name><surname>Szwajda</surname><given-names>A</given-names></string-name>, <string-name><surname>Shakyawar</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis</article-title>. <source>J Chem Inf Model</source><year>2014</year>;<volume>54</volume>:<fpage>735</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">24521231</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The UniProt Consortium.</collab></person-group><article-title>UniProt: a worldwide hub of protein knowledge</article-title>. <source>Nucleic Acids Res</source><year>2019</year>;<volume>47</volume>:<fpage>D506</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">30395287</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thin</surname><given-names>N</given-names></string-name>, <string-name><surname>Huang</surname><given-names>L</given-names></string-name>, <string-name><surname>Tomas</surname><given-names>PQ</given-names></string-name></person-group><etal>et al</etal><article-title>GraphDTA: predicting drug-target binding affinity with graph neural networks</article-title>. <source>Bioinformatics</source><year>2021</year>;<volume>37</volume>:<fpage>1140</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">33119053</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>DS</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>YD</given-names></string-name>, <string-name><surname>Guo</surname><given-names>AC</given-names></string-name></person-group><etal>et al</etal><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res</source><year>2018</year>;<volume>46</volume>:<fpage>D1074</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>G</given-names></string-name>, <string-name><surname>Yang</surname><given-names>M</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name></person-group><etal>et al</etal><article-title>De novo prediction of drug-target interactions using Laplacian regularized schatten p-Norm minimization</article-title>. <source>J Comput Biol</source><year>2021</year>;<volume>28</volume>:<fpage>660</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">33481664</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xia</surname><given-names>L-Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H</given-names></string-name></person-group><etal>et al</etal><article-title>Improved prediction of drug-target interactions using Self-Paced learning with collaborative matrix factorization</article-title>. <source>J Chem Inf Model</source><year>2019</year>;<volume>59</volume>:<fpage>3340</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">31260620</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>M</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>H</given-names></string-name></person-group><etal>et al</etal><article-title>Drug repositioning based on multi-view learning with matrix completion</article-title>. <source>Brief Bioinform</source><year>2022</year>;<volume>23</volume>.</mixed-citation>
    </ref>
    <ref id="btad524-B35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yazdani-Jahromi</surname><given-names>M</given-names></string-name>, <string-name><surname>Yousefi</surname><given-names>N</given-names></string-name>, <string-name><surname>Tayebi</surname><given-names>A</given-names></string-name></person-group><etal>et al</etal><article-title>AttentionSiteDTI: an interpretable graph-based model for drug-target interaction prediction using NLP sentence-level relation classification</article-title>. <source>Brief Bioinform</source><year>2022</year>;<volume>23</volume>:bbac272.</mixed-citation>
    </ref>
    <ref id="btad524-B36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>H</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>K</given-names></string-name></person-group><etal>et al</etal><article-title>HyperAttentionDTI: improving drug-protein interaction prediction by sequence-based deep learning with attention mechanism</article-title>. <source>Bioinformatics</source><year>2022</year>;<volume>38</volume>:<fpage>655</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">34664614</pub-id></mixed-citation>
    </ref>
    <ref id="btad524-B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname><given-names>S</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>Predicting drug-protein interaction using quasi-visual question answering system</article-title>. <source>Nat Mach Intell</source><year>2020</year>;<volume>2</volume>:<fpage>134</fpage>–<lpage>40</lpage>.</mixed-citation>
    </ref>
    <ref id="btad524-B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>N</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>D</given-names></string-name>, <string-name><surname>Wang</surname><given-names>W</given-names></string-name></person-group><etal>et al</etal>; <collab>China Novel Coronavirus Investigating and Research Team</collab>. <article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title>. <source>N Engl J Med</source><year>2020</year>;<volume>382</volume>:<fpage>727</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
